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Glucose homeostasis is normally maintained by a balance 
between hepatic glucose production and glucose utilization 
by peripheral tissues (fat, muscle, and brain) (1). Insulin 
and glucagon, which are both secreted from the pancreatic 
islets, help to maintain this balance by their actions on 
peripheral tissues (primarily muscle, liver, and fat). 
Failure of the body to regulate blood glucose levels 
properly can lead to a variety of disorders, the most common 
of which is diabetes mellitus. 
Diabetes mellitus is a heterogeneous disease that is 
characterized by hyperglycemia with insulin resistance of 
peripheral tissues and a deficiency of adequate insulin 
levels to lower blood glucose in the presence of a glucose 
challenge (2,3). There are two main categories of diabetes 
which fall under this definition. The first is Type I or 
Insulin-Dependent Diabetes Mellitus (IDDM), a condition 
wherein destruction of the pancreatic ~ cells leads to loss 
of insulin production and consequent loss of glycemic 
control. The result is hypoinsulinemia with hyperglycemia 
(2). The other category is Type II or Non-Insulin-Dependent 
1 
Diabetes Mellitus (NIDDM), in which patients display 
hyperglycemia, insulin resistance of peripheral tissues, 
and, in the earlier stages of the disease, hyperinsulinemia 
(1,3-9). 
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In both disorders, peripheral tissues display a 
resistance to insulin, although this resistance is 
particularly pronounced in NIDDM (2,6). Insulin initiates 
cellular actions by binding to a cell surface receptor, and 
recent studies have begun to clarify the first stages of 
insulin signaling (10). Insulin resistance in NIDDM is 
thought to result in many cases from a post-receptor defect 
in insulin signaling (1,4,8,9,ll,12). We therefore 
evaluated in an animal model of NIDDM the expression and 
function of proteins involved in the early signaling events 
following insulin binding to its receptor. We further 
examined these parameters following treatment of such 
insulin resistant diabetic animals with an anti-
hyperglycemic agent of the thiazolidinedione class known to 
lower blood glucose levels by sensitizing cells to insulin 
(13-20). In addition, an animal model of IDDM was similarly 
studied to determine if early insulin signaling events are 
altered by hyperglycemia in the absence of hyperinsulinemia. 
The goal of these studies was to gain a better understanding 
of the cause of cellular insulin resistance, as well as to 
further understand the corrective action mechanism of a 
novel class of compounds with great potential for the 
3 
treatment of non-insulin-dependent diabetes mellitus. 
CHAPTER II 
REVIEW OF RELATED LITERATURE 
overview 
The focus of this project was to study alterations in 
early steps of the insulin signaling pathway in insulin 
resistant diabetes, and to compare these alterations with 
possible defects in insulin deficient diabetes. Therefore, 
both diabetic syndromes will be discussed, followed by an 
overview of insulin signal transduction. 
Insulin Dependent Diabetes Mellitus CIDDMl 
Suspected Causes of IDDM 
Five percent of the population of the United States is 
afflicted with diabetes mellitus. Of these individuals, 
about 80-85% have NIDDM, and 15-20% have IDDM (21). IDDM, 
like NIDDM, apparently results from a mixture of genetic and 
environmental factors (21). The main defect in IDDM is a 
destruction of the pancreatic ~ cells, resulting in a loss 
of the ability to produce and secrete insulin (2). This 
insulin deficit causes two problems. First, ingested 
glucose is not utilized or disposed of by tissues 
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efficiently. Secondly, insulin deficiency stimulates 
glucagon secretion, which stimulates glucose release from 
the liver. Consequently, this results in hyperglycemia, 
dehydration, and glycosuria (2). 
5 
Although the etiology of IDDM is much more clear than 
the cause of NIDDM, there is some controversy concerning the 
primary origin of the disease. This is probably due to the 
fact that although there is a genetic predisposition to 
IDDM, environmental factors play a substantial role (22,23). 
In fact, although the incidence of IDDM is greater in 
relatives of IDDM patients (5-6%) than in the general 
population (0.3-0.5%), the concordance rate between 
identical twins is only about 34% (22). The one point that 
is agreed upon is that the cause of islet cell destruction 
is an autoimmune response targeted at the~ cells (22,24). 
Genetic Factors Leading to IDDM 
One of the strongest genetic indicators of IDDM is 
found in the Human Leukocyte Antigen (HLA) system of the 
Major Histocompatibility Complex (MHC) class II proteins. 
These are the proteins expressed on the surface of cells, in 
this case pancreatic ~ cells, which are responsible for 
recognition of "self" by the immune system (22,23). There 
are two main HLA markers which are associated with a 
predisposition to susceptibility to IDDM. The first is that 
DR3/DR4 heterozygotes have a 46-fold increased risk of 
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developing IDDM (22,23). The second is that a mutated DQ~ 
chain with an amino acid other than aspartate at position 57 
has an even stronger link with the incidence of IDDM 
(22,23). Although there is no direct association between 
the function of these proteins and the cause of IDDM, these 
genotypes have been found to be more susceptible to 
infection with Coxsackie B virus (23). Also, these MHC 
proteins may be involved in autoimmunity caused by early 
exposure to milk proteins, which is discussed below. 
Another genetic cause of type I diabetes involves 
antibodies to islet cell-specific antigens. Among the 
proteins found to cross-react with islet cell antibodies 
found in IDDM patients are glutamic acid decarboxylase 
(GAD), insulin, proinsulin, heat shock protein 65, 
carboxypeptidase H (an enzyme involved in the conversion of 
proinsulin to insulin), and glucose transporter GLUT-2 
(23,25-27). Antibodies to GAD have been found in 80% of 
recent onset type I diabetics (26). 
Environmental Factors Leading to !DOM 
Because the concordance rate of IDDM in monozygotic 
twins is only about 34%, environmental influences may also 
play a role in the development of IDDM. Environmental 
factors involved in the development of type I diabetes are 
stress, nitrosamines from smoked meat, seasonal variation, 
high nitrates, coffee, sugar, high latitude, low average 
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temperature, exposure to certain insecticides, and exposure 
to solid foods before three months of age (24,28). However, 
the two most likely environmental influences are viral 
infection and early exposure to cow's milk (23,24,28-30). 
Viral influences. Evidence for the involvement of 
viruses in IDDM centers on the presence of Coxsackie B virus 
in newly diagnosed IDDM patients, a strong correlation of 
maternal rubella infection during pregnancy and IDDM of the 
offspring, and the fact that Coxsackie BJ, Coxsackie B4, and 
retrovirus type 3 viruses can all infect human ~ cells in 
culture (29,30). In addition, SJL/J mice infected with 
Coxsackie B virus, Mengovirus, and Encephalomyocarditis 
(EMC) virus all developed IDDM (29). There is also a strong 
correlation between the Cytomegalovirus (CMV) genome and 
islet cell antibodies found in IDDM patients (23). It is 
not known whether the viruses necessarily infect the ~ cells 
themselves or if the viral-induced destruction of these 
cells are a result of antibodies directed against viral 
antigens cross-reacting with islet antigens. 
Milk proteins. Recent studies have shown that early 
exposure to cow's milk could contribute to the development 
of IDDM, and that breast-feeding of infants could have 
protective properties against this disorder (23,24,30). 
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In newly diagnosed diabetic children and in spontaneously 
diabetic rats fed cow's milk, antibodies to bovine serum 
albumin {BSA) and ~-lactoglobulin were found in high levels 
(30). Anti-BSA antibodies have been found to recognize an 
islet-specific plasma membrane protein of ~ 69,000, known 
as islet cell antibody 69 (ICA69) (24,30). Also, BSA shares 
a region of homology with the MHC class II proteins Ia, DQ, 
and DR (30). Interestingly, the region of homology between 
BSA and DQ~ includes the position 57 amino acid discussed 
above. Further, the difference between human and bovine 
serum albumin is that the human serum albumin has an 
aspartate in the region of homology with DQ~ corresponding 
to amino acid number 57, while BSA has an alanine. 
Therefore, this could partially explain an increased 
incidence of IDDM in patients with an amino acid other than 
apartate at position 57 of the DQ~ MHC protein {30). 
There is much controversy concerning all of these 
possible causes, mainly because individuals with any of 
these predisposing factors do not necessarily develop IDDM 
{24). Because of this, IDDM is thought to be a 
multifactorial disease of heterogeneous origin. 
Treatment of IDDM 
The most widely used treatment for type I diabetes is 
the administration of exogenous insulin and tight dietary 
control (2). 
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Non-Insulin-Dependent Diabetes Mellitus CNIDDM) 
The cause and Progression of NIDDM 
Insulin resistant or non-insulin dependent diabetes 
mellitus is a condition of unknown etiology which is 
associated with insulin resistance of peripheral tissues, 
hepatic glucose overproduction, and impaired ~ cell function 
(1,3-6,8,9,31-34). The result of these anomalies is 
hyperglycemia, hyperlipidemia and hyperinsulinemia in the 
earlier stages, followed by hypoinsulinemia in the later 
stages when overt NIDDM ensues {l,3,4,34). 
This condition is precipitated by both genetic and 
environmental factors {l,6-9,33,34). Unknown genetic 
factors initiate the development of diabetes, resulting in 
altered expression of diabetes-related genes. These 
alterations are exacerbated by diet and obesity to bring 
about insulin resistance and eventually overt diabetes 
{l,6,33,34). 
Although there is some controversy as to whether 
insulin resistance or pancreatic ~ cell dysfunction is the 
primary genetic defect causing diabetes, there is 
considerable evidence suggesting that insulin resistance 
occurs before~ cell dysfunction (1,6). One of the best 
arguments for insulin resistance preceeding a ~ cell defect 
is that in the early stages of NIDDM, patients exhibit 
hyperinsulinemia and resistance to exogenously supplied 
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insulin or endogenously secreted insulin (1,6). One of the 
earliest detectable defects in first-degree relatives of 
NIDDM patients is impaired insulin action in muscle and 
adipose tissues (21). In studies where individuals with a 
family history of NIDDM were followed longitudinally, 
insulin resistance appeared to be present for many years 
before the clinical onset of the disease (1). However, 
given the probable polygenic inheritance of the disease, it 
is possible that either a defect in P cell function alone or 
both insulin resistance and P cell defects are contributing 
factors in some cases (6). 
In addition to these genetic factors, other 
contributing factors are obesity and dietary conditions. In 
particular, increased abdominal obesity is associated with 
insulin resistance and increases the risk of developing 
NIDDM (1). Also, in offspring of diabetic parents, insulin 
resistance was found to increase as body weight increased 
(35). Thirdly, KK mice, which show glucose intolerance and 
insulin resistance but not hyperglycemia when fed laboratory 
chow, developed hyperglycemia and glycosuria when fed a diet 
that induced obesity (36). 
KKAY Mice as a Model of NIDDM 
The Upjohn colony of KKAY mice was originally obtained 
from Takeda Chemical Industries in Osaka, Japan. The KKAY 
mouse strain was established as a model of obese type II 
11 
diabetes for the purpose of screening antihyperglycemic 
compounds (37). The colony is maintained by crossing obese 
insulin-resistant yellow KKAY males with glucose intolerant 
KK females (37). KKAY mice originally were the result of a 
cross between albino KK mice and yellow obese mice (AY) 
(36). KK mice are an inbred strain with a diabetic 
phenotype consisting of impaired glucose tolerance, moderate 
hyperglycemia, insulin resistance of peripheral tissue, and 
hyperinsulinemia (36). The AY gene causes mice to become 
obese and also causes a yellow coat pigmentation of the 
animals carrying this gene (36). The offspring from the KK 
x AY cross consisted of four groups: yellow KK mice or KKAY 
mice (AYa, BB, Cc); albino KKAY mice (AYa, BB, cc); black KK 
mice (aa, BB, Cc); and albino KK mice (aa, BB, cc) (36). 
Therefore, the yellow offspring from the KK x AY cross 
possess the diabetic features of the KK mice as well as the 
obesity trait of the AY parent (36) . 
KKAY mice have significantly higher body weight, fat 
pad size, blood glucose and plasma insulin levels than 
nondiabetic C57Bl/6 control mice (37). In contrast to the 
elevated plasma insulin levels, KKAY mice have only a very 
small amount of pancreatic insulin as compared to C57 mice, 
suggesting that the islet cells are under considerable 
stress to secrete more insulin to meet the demand of the 
insulin-resistant tissues (37). KKAY mice also have a 
higher basal glucose uptake than C57 mice and are insulin-
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resistant as assayed by insulin-stimulated glucose transport 
into isolated adipocyte cells (18). Because of these 
observed phenotypic similarities with NIDDM, KKAY mice are 
considered an attractive model for studying obesity-linked 
type II diabetes (37). 
The only drawback to the KKAY model of insulin-
resistant diabetes is that since both parental strains 
possess diabetes-related characteristics, there is no 
genetically-related control mouse strain. C57Bl/6J mice 
have been used as controls in past studies with KKAY mice 
because in comparison with KKAY mice, C57Bl/6J mice diplay 
normal glucose, insulin, and triglyceride levels, and are 
insulin-sensitive (18,19,37). 
Treatments for NIDDM 
Past Treatments 
Regardless of the precipitating cause of NIDDM, the end 
result in overt diabetes is hyperglycemia and inadequate 
insulin secretion. To correct this condition, treatments 
for NIDDM patients have focused on increasing insulin output 
from the pancreas by oral administration of insulin 
secretagogues (11), and also by increasing exercise and by 




A recent development in the treatment of NIDDM has been 
the discovery of a new class of compounds that acts to 
sensitize tissues to insulin rather than increasing the 
secretion of insulin. These compounds, the 
thiazolidinediones, increase insulin sensitivity in Wistar 
fatty rats as well as obese insulin resistant KKAY mice 
(13-15,17,18,20). In addition, triglyceride levels, 
nonesterified fatty acids, and cholesterol levels were also 
lowered in the treated animals (15,38). The mechanism of 
action of thiazolidinediones is unknown, but several studies 
have shown that they work by increasing glucose uptake 
(18,20), altering gene expression (17-19,39-41), and 
enhancing insulin receptor kinase activity (16,42-44) 
without increasing insulin binding. Incubation of Rat-1 
fibroblasts with the thiazolidinedione troglitazone (CS045) 
reversed the inhibitory effect of high glucose on insulin-
stimulated tyrosine phosphorylation of the insulin receptor 
and the insulin receptor substrate-1 (IRS-1) (42). Also, 
epididymal fat pads from diabetic ob/ob mice pretreated with 
the thiazolidinedione ciglitazone showed an increase in 
insulin-stimulated glucose oxidation and lipogenesis as 
compared to untreated diabetic mice (45). The 
thiazolidinediones are presently in clinical trials (46). 
One compound of this class, pioglitazone, was used in our 
study in order to determine if it elicited its effects at 
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the level of insulin signal transduction. Two recent 
studies by Sizer, et al. (47) and Zhang, et al. (48) suggest 
that pioglitazone may act by directly augmenting early steps 
of signal transduction, specifically activation of 
phosphatidylinositol 3'-kinase. 
Signal Transduction 
Upon reaching its target cells (primarily muscle, 
liver, and adipose), insulin transmits its signal to the 
cell interior by binding to its receptor on the plasma 
membrane. The binding of insulin initiates an intracellular 
signaling cascade which distributes insulin's signal to the 
rest of the cell, activating insulin-dependent processes 
such as glucose uptake, glycolysis, glycogen synthesis, 
amino acid uptake, and DNA synthesis. Insulin resistance of 
peripheral tissues is due to an attenuation of insulin's 
signaling system or a defect in one or more of the processes 
of glucose metabolism. Due to the recent elucidation of the 
first steps of insulin action, it is the beginning of the 
signaling cascade which has been the focus of this study. 
Therefore, the components involved in the first stage of 
insulin signaling will be discussed. 
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The Insulin Receptor 
Structure 
The insulin receptor is a heterotetrameric structure 
composed of two a and two B subunits linked by disulfide 
bonds to yield an a 2B2 receptor (49-53). The two a subunits 
are extracellular glycoproteins, each of MW 135,000, and are 
responsible for the binding of insulin (4,54). The two B 
subunits are 95,000 MW transmembrane glycoproteins which 
contain ATP binding sites and the tyrosine kinase activity 
of the receptor (49-51,53-55). Each aB dimer is encoded by 
a gene of 22 exons located on human chromosome 19. The 
proreceptor, translated from a single mRNA, is either a 1343 
or 1355 amino acid protein depending on alternative splicing 
of exon 11, plus an additional 27 amino acid signal peptide 
at the NH2-terminal end (56). The two forms of the insulin 
receptor generated by alternative splicing of exon 11 (in 
the a subunit) are believed to have different properties. 
The A form, without exon 11, has a higher affinity for 
insulin (57). The B form, with exon 11, has a lower 
affinity for insulin (higher Km), but has an 8-fold higher 
Vmax and shows a two-fold higher insulin-stimulation of 
phosphotyrosine in the insulin receptor P subunit and a 
synthetic substrate (57,58). In addition to the splicing of 
exon 11 in the mRNA from which the protein is translated, 
alternate poly-A site selection results in two different-
sized transcripts, 9.5 and 7.5 kb. This poly-A site 
selection does not have a known role in the expression of 
the insulin receptor (59). 
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As the receptor protein is processed, the signal 
peptide is cleaved and the proreceptor is glycosylated. Two 
of these proreceptors are then joined by disulfide bonds 
within the regions corresponding to the a subunits, and then 
another cleavage event cuts each proreceptor into a and B 
subunits. The a and B subunits are also joined by disulfide 
bonds, and thus the mature insulin receptor is an a 2B2 
heterotetramer held together by disulfide bonds (56). 
Receptor Activation 
Once insulin binds to the a subunit, the receptor 
undergoes a conformational change that results in a series 
of intramolecular tyrosine autophosphorylation events and 
subsequent activation of the B subunit tyrosine kinase 
activity toward exogenous substrates (49,51,54,56). 
Autophosphorylation experiments carried out at 0°C suggest 
that tyrosine 1146 is the first residue to be phosphorylated 
in the B subunit, followed by phosphorylation of tyrosine 
1150 or 1151. This region is considered a regulatory region 
of the B subunit, since all three of these tyrosines must be 
phosphorylated in order to fully stimulate the 
phosphotransferase activity of the insulin receptor toward 
its exogenous cellular substrates (51). All of these 
tyrosine phosphorylation events seem to require lysine at 
position 1018, which is positioned in a potential ATP 
binding site. Mutation of this residue to alanine, 
arginine, or methionine inactivated the receptor kinase 
activity (56,60). 
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Once the B subunit is tris-phosphorylated in this 
region, it is further phosphorylated at tyrosine residues 
1316 and 1322. Phosphorylation of tyrosines 1316 and 1322 
does not seem to be required for activation of the B subunit 
phosphotransferase (61), although this carboxy-terminal 
region may play a role in regulating insulin's growth-
promoting effects (62). Studies by Kaliman, et al. and 
Pang, et al. have shown that this c-terminal domain of the 
receptor may be involved in negatively regulating the 
insulin receptor kinase (63,64); however, other work has 
shown that deletion of the c-terminus of the ~ subunit 
actually caused a decrease in insulin-stimulated receptor 
autophosphorylation and receptor internalization without 
changing insulin-stimulated IRS-1 phoshorylation, 
phosphitidylinositol 3'-kinase activity, glucose uptake, or 
DNA synthesis (65). In contrast to this study, Smith et al. 
found that the c-terminus of the receptor was not important 
in receptor internalization (66). 
Another important region of the insulin receptor ~ 
subunit is the juxtamembrane domain. Mutation of tyrosine 
960 to phenylalanine impaired the insulin-stimulated 
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phosphorylation of the main insulin receptor substrate, IRS-
1, as well as the activation of phosphatidylinositol 3'-
kinase and microtubule-associated protein kinase (MAPK) 
(67). Mutation of aspartate 938 to valine caused the 
tyrosine kinase of the receptor to be activated in the 
absence of insulin (68). The amino acids between positions 
954 and 965 in this region of the receptor are also involved 
in insulin-stimulated receptor internalization (67). 
Other important functional domains of the receptor 
include serine/threonine phosphorylation sites and 
glycosylation sites. The insulin receptor is known to be 
phosphorylated on serine and threonine residues after 
insulin stimulation (69-73), and there is some evidence for 
this phosphorylation inhibiting the insulin receptor kinase 
(69,70). Several studies involving mutation of serines 967, 
974, 976 and threonine 1336 showed that these sites are not 
important in insulin receptor function (72,73). In 
addition, elimination of serine phosphorylation of the 
juxtamembrane domain had no effect on insulin receptor 
autophosphorylation (71). Unlike the serine/threonine 
phosphorylation, glycosylation of the receptor is very 
important in receptor function. Mutation of the 
glycosylation sites of the a subunit caused the insulin 
receptor to be retained in the endoplasmic reticulum in the 
proreceptor form, while the ~ subunit glycosylation sites 
were found to be required for signal transduction (74). 
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Insulin Receptor Defects 
Alternative splicing of exon 11. Recent evidence 
suggests that alternative splicing of exon 11 of the insulin 
receptor may play a role in the development of NIDDM, 
although this has been controversial. Some data has shown 
that there is a higher ratio of the B form of the receptor 
(with exon 11), which has a lower affinity for insulin, in 
NIDDM patients as compared to nondiabetic controls 
(57,75-77). However, there are also reports of equal ratios 
of A and B forms between control and NIDDM patients (78,79), 
and also some reports of a higher ratio of the A form in 
NIDDM as compared to nondiabetic controls (80,81). It is 
difficult to rationalize the differences between these 
studies, but one explanation may be that different NIDDM 
groups have different ratios, or possibly that there is not 
an absolute correlation between splicing products of the 
insulin receptor and NIDDM. 
Other mutations. There are several documented 
mutations of the insulin receptor leading to insulin 
resistance, and such mutations reportedly affect the insulin 
receptor at different points in its synthesis, processing, 
binding, function, and internalization (82). The most 
severe forms of NIDDM, such as Rabson-Mendenhall syndrome 
and leprechaunism, were associated with mutations in the a 
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and~ subunits of the insulin receptor (83). However, these 
collective mutations only account for the insulin resistance 
of 1-10% of all NIDDM patients, and thus there are probably 
some other defects which cause insulin resistance in the 
majority of NIDDM patients (3,12,82,83). These other 
defects are likely to occur in intermediate steps of the 
insulin signaling pathway. 
The Insulin Receptor Substrate-1 (IRS-1) 
Structure of IRS-1 
As mentioned above, insulin binding to its receptor 
activates the tyrosine kinase activity of the receptor 
toward intracellular substrates. The main protein 
identified to be tyrosine phosphorylated upon insulin 
stimulation migrates between 160 and 185 kDa on SDS-
polyacrylamide gel electrophoresis (84-87). This protein 
has been cloned and sequenced by two separate groups from 
Fao hepatoma cells and 3T3-Ll adipocytes, and has been named 
insulin receptor substrate-! (IRS-1) (85-88). Although IRS-
1 migrates as a larger protein on SOS-PAGE, it is a 131,000 
MW hydrophilic protein, translated from a 9.5 kb mRNA. The 
difference in mobility and molecular weight is thought to be 
due to the high basal serine phorphorylation and high ~­
sheet content of IRS-1 causing the protein to migrate as a 
larger protein (85,89). Although it contains a putative ATP 
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binding site (gly1n-val-gly-glu-ala-gly- ... -lys~6-X-ile), it 
lacks the asp-phe-gly or ala-pro-glu sequences diagnostic of 
a protein kinase (85). 
Before insulin stimulation, IRS-1 exists as a 
phosphoprotein containing phosphoserine and some 
phosphothreonine but no phosphotyrosine. IRS-1 contains 35 
serine/threonine phosphorylation sites, and at least 20 
potential tyrosine phosphorylation sites (85,90). There is 
some evidence for an increase in serine/threonine 
phosphorylation on insulin stimulation (89,90), which could 
inhibit tyrosine phosphorylation of IRS-1 or inhibit the 
docking of other proteins to the activated IRS-1 {89,90). 
However, the majority of insulin stimulated phosphorylation 
of IRS-1 occurs on tyrosine residues, and this has been 
shown to activate it as a multisite docking protein {10,91). 
Tyrosine Phosphorylation and Function of IRS-1 
There are several lines of evidence which indicate that 
IRS-1 is involved in insulin signaling. First, aside from 
the IR ~ subunit, IRS-1 is the major protein phosphorylated 
on tyrosine residues after insulin stimulation 
(55,84,86,92,93). Second, phosphorylation of IRS-1 occurs 
within the same time frame and with similar insulin 
concentrations as phosphorylation of the insulin receptor B 
subunit (55,92). In fact, maximal phosphorylation of IRS-1 
in response to insulin occurs within 30 seconds, which 
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directly correlates with phosphorylation of the insulin 
receptor. This implicates IRS-1 as a direct substrate of 
the insulin receptor tyrosine kinase, since no other 
phosphorylated products are seen earlier. Third, an insulin 
receptor mutated at tyrosine 960 of the juxtamembrane region 
and transf ected into CHO cells was unable to phosphorylate 
IRS-1 in response to insulin stimulation, nor was this 
receptor capable of mediating normal cellular responses to 
insulin such as stimulation of glycogen synthase, amino acid 
uptake, or thymidine uptake into DNA, even though this 
receptor was still able to phosphorylate itself and other 
exogenous substrates (50). Likewise, mutation of the ATP 
binding site lysine-1018 prevented insulin receptor 
autophosphorylation and IRS-1 phosphorylation in the 
presence of insulin (60). Also, cells expressing receptors 
with a mutation of tyr-1146 to phenylalanine had impaired B 
subunit autophosphorylation as well as impaired IRS-1 
phosphorylation (94). 
IRS-1 function has been linked to both the metabolic 
(95-102) and mitogenic (90,97,103-107) actions of insulin. 
An example of the mitogenic involvement of IRS-1 in insulin 
signaling is shown in studies with Chinese hamster ovary 
(CHO) cells. Expression of IRS-1 in CHO cells doubles the 
maximal amount of thymidine incorporation into DNA 
stimulated by insulin, and expression of IRS-1 antisense RNA 
in CHO cells reduced the mitogenic response to insulin 
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(89,108). Similarly, Xenopus oocytes, which have very 
little or no IRS-1 and which normally do not mature in 
response to insulin or IGF-1, were found to mature in 
response to insulin and IGF-1 when IRS-1 was transfected 
into these cells {106). Other data showed that disruption 
of IRS-1 gene expression in transgenic mice caused a 
decrease in intrauterine and postnatal growth by more than 
50% (90,109,110). The strongest evidence supporting a role 
for IRS-1 in the metabolic effects of insulin comes from the 
association of IRS-1 with phosphatidylinositol 3'-kinase. 
IRS-1 has been shown to associate with and activate 
phosphatidylinositol 3'-kinase on insulin stimulation 
{111-115). The catalytic activity of phosphatidylinositol 
3'-kinase can be specifically inhibited by a fungal toxin, 
wortmannin, and this action results in inhibition of 
insulin-stimulated glucose uptake (95,96,99,102), thus 
linking IRS-1 and PI3K with a well-known metabolic response 
to insulin. 
As mentioned above, once IRS-1 becomes tyrosine 
phosphorylated by the insulin receptor kinase, it acts as a 
multisite docking protein via an interaction of its 
phosphotyrosine residues with src-homology 2 {SH2) domains 
of several target proteins {10). SH2-containing proteins 
that interact with IRS-1 on insulin stimulation include the 
p85a subunit of phosphatidylinositol 3'-kinase (PI3K), the 
tyrosine phosphatase Syp/SH-PTP2/PTP1D, growth factor 
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receptor bound protein 2 (GRB2), and Nck (10,91,116-120). A 
schematic diagram of this is shown in fig. 1, adapted from 
White and Khan, 1994 (10). The specificity of these 
interactions is determined by the sequences surrounding 
Glucose 
Transport 
Fig. 1. Early steps in insulin signal transduction. 
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the phosphorylated tyrosines (pY) of IRS-1 and the sequence 
of each SH2 domain on the target proteins. The p85a subunit 
of PI3K prefers pYMXM motifs (phosphotyrosine-methionine-any 
amino acid-methionine), specifically pY608 and pY939 of IRS-
1 (91). GRB2 binds to pY(895)VNI (phosphotyrosine-valine-
asparagine-isoleucine) (91), while Nck binds most strongly 
to pY(147)DTG (phosphotyrosine-aspartate-threonine-glycine) 




Mutations in IRS-1 
When the incidence of amino acid mutations in the IRS-1 
gene was compared between NIDDM patients and nondiabetic 
control subjects, two mutations were found: a glycine to 
arginine transition at position 972 and an alanine to 
proline transition at amino acid 513 (122). Of the 86 NIDDM 
patients and 76 normoglycemic controls studied, ten NIDDM 
patients and 3 controls were heterozygous for the position 
972 polymorphism, while 6 NIDDM patients and 2 controls were 
heterozygous for the position 513 polymorphism. There were 
no homozygotes or double heterozygotes with both 
polymorphisms. Another study of French NIDDM families found 
that these same polymorphisms did not cosegregate with 
diabetes (123). A different study compared tandem repeat 
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mutations in the IRS-1 gene between Japanese NIDDM families 
and controls, and found that tandem repeat polymorphisms 
were not associated with a higher risk of NIDDM (124). 
Therefore, no direct link exists between these naturally 
occurring IRS-1 mutations and NIDDM. 
Proteins which Associate with Phosphorylated IRS-1 
Phosphatidylinositol 3'-Kinase (PI3K) 
The phosphatidylinositol 3'-kinase (PI3K) is composed 
of an 85 kDa adaptor subunit and a 110 kDa catalytic subunit 
(52,125-128). The 110 kDa subunit is a 1068 amino acid 
protein which is related to Vps34p, a Saccharomyces 
cerevisiae protein involved in the sorting of proteins to 
the vacuole {127). It catalyzes the phosphorylation of the 
D-3 position of the inositol ring of phosphatidylinositol 4-
phosphate and phosphatidylinositol 4,5-bisphosphate (52,125, 
126). This reaction would yield phosphatidylinositol 3,4-
bisphosphate and phosphatidylinositol 3,4,5 trisphosphate, 
respectively. The biological function of these products is 
unknown, but as mentioned above, inhibition of the pllO 
catalytic activity with the fungal toxin wortmannin 
inhibited insulin-stimulated glucose uptake by blocking 
recruitment of vesicles containing GLUT4 transporter 
proteins to the plasma membrane via an unknown mechanism 
(95,96,99,102,129). The phosphatidylinositol 3'-phosphate 
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products of PI3K action are not cleaved by phospholipase c, 
but they have been shown to activate the r, o, ~' and € 
isoforms of protein kinase c (130,131). 
PI3K may also be involved in insulin-stimulated 
mitogenesis (106,107). The stimulation of Xenopus laevis 
oocyte maturation by IGF-I or insulin requires the presence 
of IRS-1 and the activation of PI3K through its association 
with IRS-1 (106). Also, microinjection of N- or c-terminal 
SH2 domains of p85a into rat-1 fibroblasts stably 
transfected with human insulin receptors inhibited insulin-
stimulated DNA synthesis (107). Likewise, microinjection of 
pYMXM or pYXXM phosphonopeptides into the same cell line 
inhibited DNA sythesis from 61-68% as compared to control 
cells (107). 
The pllO subunit requires the p85a subunit in order to 
function (127). The p85a subunit contains 2 SH2 domains and 
1 SH3 domain (85,94,125,132), and may be phosphorylated on 
insulin stimulation, although this is controversial (85,94, 
100,114,125,133). There is an overwhelming amount of data 
showing that the p85a subunit of PI3K associates with 
tyrosine-phosphorylated IRS-1 on insulin stimulation, and 
that this association causes PI3K activation (10,91,100,102, 
106,111-113,115,119,134-137). Strong evidence in favor of 
the importance of the association of IRS-1 with p85a in PI3K 
activation involves the use of synthetic peptides. In vitro 
activation of immunopurified PI3K by recombinant IRS-1 was 
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inhibited by the addition of bacterial fusion proteins 
containing the SH2 domains of p85a {100,119). Likewise, 
addition of phosphorylated pYMXM motifs from IRS-1 activated 
PI3K in vitro {100,112,119). In addition to these data, 
PI3K activity was found in anti-IRS-1 immunoprecipitations 
from insulin stimulated cells of a variety of types 
{10,101,111,126,135,136,138,139). 
Growth Factor Receptor Bound Protein-2 CGRB2) 
Growth factor receptor bound protein-2 {GRB2) is a 24 
kDa protein containing one SH2 domain flanked by two SH3 
domains, and has no known catalytic function of its own 
{140). As mentioned above, GRB2 associates with IRS-1 on 
insulin stimulation through its SH2 domains and the 
pY{895)VNI motif of IRS-1 {10,91,120,141,142). 
GRB2 also associates with another protein, She, on 
insulin stimulation {10,105,116,141-145). She, or src-
homology/collagen protein, has one SH2 domain and a 
glycine/proline rich stretch which is homologous to 
collagen. It has no SH3 domain and no catalytic function of 
its own (145). She is also tyrosine phosphorylated on 
insulin stimulation by the insulin receptor kinase, and it 
is the tyrosine-phosphorylated form of She which binds the 
SH2 domain of GRB2 {143,145). This is shown in fig. 1. 
The function of GRB2 lies in its ability to bind to 
other proteins. The N- and c-terminal SH3 domains bind to a 
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proline-rich stretch in the c-terminus of the guanine 
nucleotide exchange factor son of sevenless {SOS) (144,146). 
sos then activates ras, which binds the serine/threonine 
kinase raf-1 {10). Raf-1 is then activated to phosphorylate 
MAP kinase kinase, leading to activation of MAP kinase 
{10,105,116,140,144,146-148) and DNA synthesis {10,116,141, 
148). Another consequence of increased activation of ras or 
raf-1 is the increased expression and activity of the 
glucose transporter GLUTl but not GLUT4. This results in 
increased basal glucose uptake regardless of insulin levels 
{149-151). The SH3 domains of GRB2 are also responsible for 
localization of GRB2 to membrane ruffles {152). Recent 
evidence has shown that a substrate of MAP kinase, PHAS-I, 
is involved in insulin activation of translation initiation 
{153), suggesting yet another downstream effect of insulin 
signaling through GRB2 and ras or raf-1. 
A third function of the SH3 domains of GRB2 is to 
associate with the proline-rich stretch of the GTPase 
protein dynamin. GRB2 associates with dynamin in 
unstimulated cells, and this complex then associates with 
phosphorylated IRS-1 on insulin stimulation via the SH2 
domain of GRB2 {140,154). Association of the GRB2-dynamin 
complex with phosphorylated IRS-1 or phosphopeptides 
containing the sequence of IRS-1 which binds to the GRB2 SH2 
domain activated the GTPase activity of dynamin (154). The 
significance of this complex in insulin signaling is 
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unknown, but dynamin may be involved in the pinching off of 
coated vesicles from the plasma membrane for endocytosis, 
and thus it could possibly be involved in receptor 
internalization {154). Transfection of mammalian cells with 
mutant dynamin blocked receptor-mediated endocytosis (154). 
Another protein found to associate with IRS-1 on 
insulin stimulation is Nck, a 47 kDa protein composed almost 
entirely of one SH2 and three SH3 domains (155). The 
function of Nck is unknown, but it may bind to a protein 
with serine/threonine kinase activity via its SH3 domains 
{156), and overexpression of Nck causes cell transformation 
and cell proliferation (155,157). 
Syp/PTP1D/SH-PTP2 
Syp is a 65-72 kDa protein tyrosine phosphatase with 
two SH2 domains in its N-terminus, and differs from the 
other IRS-1 binding proteins in that it has a well-
characterized catalytic domain {117). It has also been 
called PTPlD or SH-PTP2 by separate groups. Syp has been 
shown to bind to tyrosine-phosphorylated IRS-1 {91,117), and 
incubation with IRS-1 phosphopeptides caused up to a 50-fold 
stimulation of the phosphotyrosine phosphatase activity of 
Syp in vitro {121). Syp also binds to and is tyrosine-
phosphorylated by the insulin receptor in vitro on insulin 
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stimulation (158-160). Recent studies have provided 
evidence indicating that syp is linked to insulin, IGF-1, or 
EGF stimulation of DNA synthesis. Xiao, et al. showed that 
in rat-1 fibroblasts stably expressing the insulin receptor, 
insulin~stimulated DNA synthesis was inhibited by 
microinjection of anti-Syp antibodies, phosphonopeptides 
containing the IRS-1 phosphotyrosine binding sites for Syp 
SH2 domains, or Syp SH2-GST fusion proteins by 60-90%, 50-
60%, and 90%, respectively (161). Similar inhibition of DNA 
synthesis was seen with IGF-I and EGF stimulation of these 
cells under the same conditions, although serum-stimulated 
DNA synthesis was not affected by these inhibitors (161). 
Therefore, there are factors in serum other than insulin, 
IGF-I, or EGF that stimulate DNA synthesis independently of 
Syp. 
Hypothesis and Specific Aims 
Because NIDDM is associated with a variety of metabolic 
derangements (2-5,120), and because the cause of insulin 
resistance probably lies in a post-receptor defect in most 
cases, this project focused on studying early insulin 
signaling events as possible sites of defects leading to 
insulin resistance and NIDDM. The rationale for our 
hypothesis is that early defects would lead to a greater 
variety of derangements downstream, before insulin's signal 
branched off to elicit its many different effects. Such a 
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rationale is supported by the observation that two rare but 
very severe forms of NIDDM, leprechaunism and Rabson-
Mendenhall syndrome, result from defects in insulin's 
initial signaling events; i.e., receptor binding and 
autophosphorylation {83). 
Hypothesis 
The overall hypothesis of this dissertation is that a 
primary defect in insulin resistance is an altered 
expression or function of an early insulin signaling 
component, and that this defect is corrected or compensated 
for by the antihyperglycemic agent pioglitazone. 
Specific Aims 
To test this hypothesis, two models of insulin 
resistant diabetes were used. The insulin resistant KKAY 
mice were used as an animal model for insulin resistant 
diabetes because such mice are obese, glucose intolerant, 
and exhibit hyperglycemia and hyperinsulinemia {36). 
Differentiated 3T3-Ll adipocytes pre-fed with high glucose 
and high insulin concentrations were used as an in vitro 
model of insulin resistance. In addition, rats made insulin 
deficient with streptozotocin treatment were studied to 
determine the effect of hyperglycemia in the absence of 
hyperinsulinemia on early insulin signal transduction 
events. 
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Specific Aim 1 
To determine if the expression of the insulin receptor, 
IRS-1, PI3K p85a, GRB2, Nck, or Syp is altered in liver and 
fat tissues of KKAY mice as compared to control nondiabetic 
mice. 
Protein levels. First, the protein levels of these 
insulin signaling components were compared between KKAY 
diabetic mice and control diabetic mice. 
mRNA levels. When the protein levels were found to be 
altered between diabetic and nondiabetic animals, the mRNA 
levels were examined to determine if the alteration was a 
result of a difference in the abundance of the mRNA for 
these genes. 
Specific Aim 2 
To determine if the insulin-stimulated tyrosine 
phosphorylation of the insulin receptor or IRS-1 is 
defective in KKAY mice as compared to nondiabetic control 
mice. 
Isolated epididymal adipocytes. The acute insulin-
stimulated tyrosine phosphorylation of the insulin receptor 
and IRS-1 was examined in isolated epididymal adipocytes 
from KKAY and control mice by immunoblotting cell extracts 
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with anti-phosphotyrosine antibodies. 
Specific Aim 3 
To determine if the insulin-stimulated association of 
IRS-1 to PI3K p85a is defective in KKAY mice as compared to 
nondiabetic mice. 
Isolated epididymal adipocytes. Cell extracts from 
isolated epididymal adipocytes were acutely stimulated with 
insulin, immunoprecipitated for IRS-1, and immunoblotted for 
PI3K p85a. 
Specific Aim 4 
To determine if any of the alterations observed in aims 
1-3 were corrected by treatment of animals with the insulin-
sensitizing agent pioglitazone. 
Pioglitazone treatment of KKAY mice. A third group was 
included in the studies in aims 1-3 which consisted of KKAY 
mice treated with pioglitazone. Because the cellular 
mechanism of pioglitazone action is unknown, the purpose of 
this aim was to determine if pioglitazone treatment affected 
early insulin signaling events. 
Specific Aim 5 
To determine if the alterations observed above in KKAY 
mice were due to the high levels of insulin and glucose 
associated with the diabetic condition. 
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High glucose and high insulin. Differentiated 3T3-Ll 
adipocyte cell cultures were treated overnight with medium 
containing high levels of glucose and insulin, thus 
representing the hyperglycemic and hyperinsulinemic state 
seen in the diabetic KKAY mice. The expression of early 
insulin signaling components in this model was compared to 
the expression of these factors in control cells pre-fed for 
the same time interval with low glucose and low insulin 
levels. In addition, the ability of insulin to stimulate 
receptor autophosphorylation and IRS-1 phosphorylation was 
also analyzed in this model. 
High glucose. To determine if any alterations observed 
in insulin-resistant mice were due to high blood glucose 
levels, the expression of these insulin signaling mediators 
was studied in rats made insulin-deficient by streptozotocin 
treatment. 
Significance 
Because the cause of NIDDM is unknown in the majority 
of cases, the search for defects leading to this condition 
is of extreme importance for developing preventive and 
therapeutic strategies. Identification in the last few 
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years of proteins involved in insulin signaling has provided 
a starting point for the search for defects in insulin 
signaling leading to insulin resistance. Once the likely 
defects are identified, it is possible that the development 
of new antidiabetic compounds could be aimed at these points 
of signal breakdown. This study has included the 
antidiabetic agent pioglitazone, a member of a novel class 
of insulin-sensitizing compounds. This class of compounds is 
known to lower blood glucose levels of diabetic mice by an 




MATERIALS AND METHODS 
Materials 
General Chemicals and Supplies 
Guanidinium thiocyanate and f ormamide were purchased 
from International Biotechnologies, Inc. (New Haven, CT). 
Acrylamide/Bis (40%), ammonium persulfate, and TEMED were 
obtained from Bio-Rad (Richmond, VA). Protein A-Sepharose 
was purchased from Pharmacia (Milwaukee, WI). Nytran nylon 
membranes (Schleicher and Schuell, Keene, NH) and Immobilon 
PVDF membranes (Millipore, Bedford, MA) were used for 
northern and western blotting, respectively. Tris and 
glycine were purchased from Fisher Scientific (Pittsburgh, 
PA). The Riboprobe kit, including all nucleotides, 
polymerases, and transcription buffers were obtained from 
Promega Corp. (Madison, WI). 32P-CTP, 14C-Deoxyglucose, and 
the Enhanced ChemiLuminescence reagents were purchased from 
Amersham (Arlington Heights, IL). Luria-Bertani broth 
(dehydrated) was obtained from Difeo (Detroit, MI). All 
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other chemicals were purchased from Sigma Chemical Co. (St. 
Louis, MO). 
Culture Reagents 
Dulbecco's Modified Essential Medium (DMEM) with high 
glucose (25 mM) or low glucose (5 mM) were obtained from 
BioWhittaker (Walkersville, MD). Fetal Calf Serum and Calf 
Serum (heat inactivated), glutamine, trypsin-EDTA, 
dexamethasone, IBMX (3-isobutyl-1-methylxanthine), 
endotoxin-free water, Antibiotic/Antimycotic solution 
(lOOX), and no-glucose DMEM (for glucose transport assays) 
were all obtained from Sigma Chemical Corp. (St. Louis, MO). 
Porcine insulin obtained from Eli Lilly (Indianapolis, IN) 
was used for the acute stimulation studies, and bovine 
insulin (Sigma Chemical Corp. (St. Louis, MO) was used 
during differentiation of 3T3-Ll adipocytes. 
cDNA Constructs 
The Insulin Receptor 
Mouse insulin receptor cDNA was obtained from Dr. 
Graeme Bell (University of Chicago, Chicago, IL) in pUC, and 
a 775 bp insert was subcloned into the EcoRI site of pGEM3Z 
(2743 bp) giving a total construct size of 3518 bp. For 
Riboprobe preparation, the plasmid was linearized with 
HindIII and T7 polymerase was used to make antisense mRNA. 
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This probe hybridizes to two transcripts of 9.5 and 7.5 kb, 
which differ by alternate poly-A site selection (59). 
The Insulin Receptor Substrate-1 
A rat cDNA insert of 5.5 kb in pBluescript was obtained 
from Dr. Morris White (Joslin Diabetes Center, Boston, MA) 
(85). For Riboprobe preparation, the construct was 
linearized with BamHI and T7 polymerase was used to make 
antisense mRNA. The size of the transcript that hybridizes 
with this Riboprobe is 9.5 kb. 
Phosphatidylinositol 3'-kinase p85a 
A rat cDNA insert of 1550 bp in pBluescript SK+/- was 
obtained from Dr. Lewis Cantley {Harvard Medical School, 
Boston, MA). Digestion of this construct for Riboprobe 
preparation with PvuII generates 3 fragments: a -2900 bp 
vector fragment, a -700 bp fragment, and a -900 bp fragment. 
The antisense mRNA probe created with T7 polymerase is 
approximately 760 bp, transcribed from the -700 bp fragment. 
The main transcript recognized by northern blotting in most 
tissues is 7.5 kb. 
Antibodies 
Anti-Insulin Receptor 8-subunit 
A polyclonal antibody directed against the c-terminus 
of the insulin receptor ~ subunit was obtained from Dr. 
Morris White (Joslin Diabetes Center, Boston, MA). 
Anti-Insulin Receptor Substrate-1 
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Immunoprecipitations. A polyclonal antibody directed 
against a c-terminal 14 amino acid peptide from rat liver 
IRS-1 was purchased from Upstate Biotechnologies, Inc. (Lake 
Placid, NY) and used for immunoprecipitation of IRS-1 from 
mouse primary adipocytes. For immunoprecipitation of IRS-1 
from mouse tissue, a polyclonal antibody directed against a 
baculovirus-overexpressed IRS-1 was obtained from Morris 
White (Joslin Diabetes Center, Boston, MA). 
Western blotting. For primary adipocyte experiments, 
rat experiments, and 3T3-Ll experiments, the anti-c-terminus 
antibody described above was used for western blotting. For 
western blotting of mouse tissue immunoprecipitates, a 
monclonal antibody directed against IRS-1 was obtained from 
Morris White (Joslin Diabetes Center, Boston, MA). 
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Anti-Phosphotyrosine 
Tyrosine phosphorylation of the insulin receptor and 
IRS-1 was detected using a monoclonal anti-phosphotyrosine 
antibody, which was purchased from Upstate Biotechnologies, 
Inc. (Lake Placid, NY). This antibody, named 4GlO, was 
generated using phosphotyramine, and recognizes tyrosine-
phosphorylated proteins. 
Anti-Phosphatidylinositol 3'-kinase p85a 
For detection of PI3K p85a in all experiments except 
for the primary adipocytes, a monoclonal antibody directed 
against the N-terminal SH2 domain was obtained from Upstate 
Biotechnologies, Inc. (Lake Placid, NY). In the primary 
adipocyte experiments, a monoclonal antibody specific for 
the SH3 domain of PI3K p85a, also purchased from Upstate 
Biotechnologies, Inc., was used to measure PI3K p85a in 
anti-IRS-1 immunoprecipitates. 
Anti-Growth Factor Receptor Bound Protein-2 
Anti-GRB2 monoclonal antibody was obtained from 
Transduction Laboratories (Lexington, KY). This antibody 




Anti-Nck monoclonal antibody was obtained from 
Transduction Laboratories (Lexington, KY). It was generated 
using an 11.5 kDa fragment corresponding to amino acid 
positions 279-377 of the human Nck protein. This antibody 
cross-reacts with Nck in mouse and rat lysates. 
Anti-Syp 
For detection of Syp in all experiments, an anti-Syp 
monoclonal antibody was obtained from Transduction 
Laboratories (Lexington, KY). The anti-Syp antibody was 
produced using a polypeptide consisting of the N-terminal 
177 amino acids of the human Syp protein. 
Anti-Mouse 
Anti-mouse Ig antibody (from sheep) was purchased from 
Amersham (Arlington Heights, IL). This antibody was 
conjugated to horseradish peroxidase (HRP) for use as a 
secondary antibody in enhanced chemiluminescence detection 
(ECL) of proteins which are recognized by monoclonal (mouse) 
primary antibodies. 
Anti-Rabbit 
Anti-rabbit Ig antibody (from donkey) was purchased 
from Amersham (Arlington Heights, IL). This antibody was 
conjugated to horseradish peroxidase for use as a secondary 
antibody in ECL detection of proteins which are recognized 
by a polyclonal (rabbit) primary antibody. 
Positive Controls 
Insulin Receptor Substrate-1 
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Chinese hamster ovary cells overexpressing IRS-1 were 
obtained from Morris White (Joslin Diabetes Center, Boston, 
MA). An aliquot of total cell lysate from these cells was 
used as a positive control for all experiments involving the 
detection of IRS-1. 
Phosphatidylinositol 3'-kinase 
Baculovirus-overexpressed PI3K p85a was obtained from 
Dr. Lewis Cantley (Harvard Medical School, Boston, MA), and 
an aliquot of this protein extract was used as a positive 
control for all experiments involving detection of PI3K 
p85a. This protein migrated on SOS-PAGE as 85 kDa and was 
recognized by the anti-PI3K p85a antibodies with high 
affinity. 
Experimental Models and Design 
Insulin Resistant Model (NIDDM) 
All animal work up until the point of protein or RNA 
extraction was performed at The Upjohn Company, including 
blood glucose and serum insulin determinations. 
C57 Control Mice 
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Male C57Bl-J6 mice 10-12 weeks of age were obtained 
from Charles Rivers (Portage, MI) as control animals with 
normal blood glucose (170±6 mg/dl or 9.4±0.3 mM) and normal 
serum insulin levels ( 2 6±3 µU /ml or 1. 9x10-10 M) . 
KKAY Diabetic Mice 
Obese male KKAY mice 10-12 weeks of age were obtained 
from the Upjohn Company (Kalamazoo, MI) for use as an animal 
model of insulin-resistant diabetes (NIDDM) . KKAY mice 
result from a cross between glucose-intolerant black KK 
female mice and yellow obese male AY mice. The yellow 
offspring KKAY mice are obese and insulin resistant, and 
display marked hyperinsulinemia and hyperglycemia (19,36). 
Due to the diabetic characteristics of the parental 
strains, no genetically matched control exists for this 
model for this model. Therefore, C57Bl/6J mice were used as 
controls because of the relatively normal glucose regulation 
in the C57 strain. 
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Feeding and Pioglitazone Treatment 
All animals were housed individually and fed ad libitum 
for four days prior to the experiment with or without 
pioglitazone delivered as a food admixture at about 20 
mg/kg/day. It was previously determined that this dose and 
delivery method produced maximal changes in blood glucose 
and insulin sensitivity in mice within four days {Jerry 
Colca, The Upjohn Company, Kalamazoo, MI, unpublished 
observations). 
Tissue Extraction and Animal Processing 
On the fifth day from the start of drug treatment, the 
mice were bled from the orbital sinus for measurement of 
blood glucose concentrations and serum insulin levels, 
decapitated, and liver and epididymal fat pads were excised. 
The tissues were rapidly frozen in liquid nitrogen, shipped 
to us on dry ice, and stored at -70° C until they were 
processed by the RNA preparation or protein preparation 
protocols. Blood glucose levels were determined with an 
Alpkem Glucose AuotoAnalyzer {Alpkem, Clackamas, OR), and 
serum insulin levels were determined by radioimmunoassay as 
previously described {162). 
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Primary Adipocytes 
Isolated/Primary Adipocyte Preparation 
Animals used for the isolated adipocyte studies were 
treated exactly as the above animals regarding feeding, 
pioglitazone treatment, and animal sacrifice until the point 
of tissue excision. Epididymal fat pads from C57 and KKAY 
mice treated with or without pioglitazone were placed into 
KRB buffer (Krebs-Ringer-Bicarbonate-BSA = 128 mM NaCl, 5 mM 
KCl, 1.4 mM CaC12 , 1.3 mM MgS04•7H20, 5 mM NaHC03 , 1.1 mM 
glucose, and 2% BSA), quickly minced, and incubated in KRB 
with 200 units/ml collagenase for 20 minutes. Epididymal 
fat pads from six animals from each group were combined to 
generate a pool of adipocytes which were later split into 
five samples to be individually stimulated with insulin. 
The entire experiment was performed twice. The collagenase-
digested fat pads were then passed through a cell strainer 
which allowed digested cells and buffer to flow through. 
The cells were washed twice in KRB buffer, then aliquots 
were delivered into 0.4 ml microfuge tubes containing 0.1 ml 
dinonylpthalate oil and centrifuged briefly at 3000 x g to 
separate the buoyant fat cells from the non-adipose cells. 
Adipocytes were then pooled again, pre-incubated in KRB for 
five minutes, and cells were distributed in equal volume 
aliquots (0.25 ml) for insulin stimulation. 
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Insulin Stimulation 
Equal volume aliquots of adipocytes (5 samples per 
group) were incubated with 1x10-7 M insulin for two minutes 
at 37° C with gentle shaking. The samples were then quickly 
frozen in a dry ice-acetone bath and stored at -70° C until 
the time of the protein extraction. 
Insulin Deficient Model (IDDM) 
As with the insulin-resistant model, all animal work up 
until the point of protein or RNA preparation was performed 
at The Upjohn Company. 
control Rats 
Male Sprague-Dawley rats (160-180g) (Charles Rivers, 
Portage, MI) were used as control animals for the 
experiments dealing with insulin-deficient diabetes. 
Insulin-Deficient Rats 
Male Sprague-Dawley rats (160-180g) were made insulin 
deficient by tail-vein injection of streptozotocin (65 
mg/kg) and allowed to recover for 7 days prior to tissue 
extraction for protein or RNA preparation. These animals 
displayed serum insulin levels of 4.2±1.0 µU/ml (3.1x10-
11±0. 7x10-11 M) compared to 22.8±1.8 µU/ml (1.7x10-10±0.1x10-10 M) 
in the controls. Streptozotocin-treated rats also posessed 
high blood glucose levels (459±10 mg/dl or 25.5±0.5 mM) as 
compared to control rats (151±2 mg/dl or 8.4±0.l mM). 
Tissue Extraction and Animal Processing 
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On the day of the experiment, the rats were bled from 
the orbital sinus for measurement of blood glucose 
concentrations and blood insulin levels, decapitated, and 
liver and epididymal fat pads were excised. The tissues 
were rapidly frozen in liquid nitrogen, shipped to us on dry 
ice, and stored at -70° c until they were processed by the 
RNA preparation or protein preparation protocols. Blood 
glucose levels were determined with an Alpkem Glucose 
AuotoAnalyzer (Alpkem, Clackamas, OR), and serum insulin 




3T3-Ll cells were obtained from the laboratory of Dr. 
Howard Green (Harvard Medical School, Boston, MA). 3T3-Ll 
cells were cultured on 100 mm plates (Corning, Oneonta, NY) 
in a Napco Model 6200 incubator (Napco Scientific Co., 
Tualatin, OR) at 37° c and 10% C02 , and fed with the 
appropriate medium every 2-3 days. In the culturing of 3T3-
Ll adipocytes, "high glucose" medium refers to Dulbecco's 
Modified Eagle's Medium (DMEM) containing 4.5 g/L glucose 
(450 mg/dl or 25 mM), and "low glucose" medium refers to 
DMEM containing 1.0 g/L glucose (100 mg/dl or 5.5 mM). 
Differentiation 
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Undifferentiated preadipocytes were grown to confluence 
in high glucose DMEM + 10% calf serum. Two days post-
conf luence, the cells were cultured in differentiation 
medium (high glucose + 10% fetal calf serum, 1. 6x10-1 M 
insulin, 0.25 µM dexamethasone, and 0.5 mM IBMX). After two 
days in differentiation medium, the cells were fed with high 
glucose DMEM + 10% fetal calf serum and 1. 6x10-1 M insulin 
for an additional two days. The cells were then cultured in 
high glucose DMEM + 10% fetal calf serum for 6 days, at 
w~ich time they were determined to be at least 90% confluent 
by visual assessment. 
Pre-feeding Conditions 
Control Cells - Low Glucose, No Insulin. 
Differentiated control cells were cultured in low glucose 
DMEM + 0.5% serum substitute for 20-24 hours prior to the 
experiment. 
Insulin Resistant Cells - High Glucose, High Insulin. 
Differentiated cells to be used as a model of the insulin 
resistant condition were cultured in high glucose DMEM + 
0.5% serum substitute and 2x10~ M insulin for 20-24 hours 
prior to the experiment. 
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Insulin debinding procedure. This procedure was used 
to release any bound insulin from the overnight high insulin 
incubation, and was related to our laboratory through 
personal communication (Jonathan Whittaker, SUNY Health 
Science Center, Stonybrook, NY, phone conversation in April, 
1992). It is a variation on a method which was previously 
published (163). Immediately prior to glucose transport 
assays or acute insulin stimulation of cells for protein 
preparations, all cell groups were rinsed twice in PBS (pH 
6.8), incubated in PBS (pH 6.8) + 1% BSA for 45 minutes, and 
then rins~d again in PBS (pH 6.8). 
Glucose Transport Assay 
3T3-Ll cells were grown in Costar 6-well plates 
(Cambridge, MA), differentiated, pre-fed, and incubated with 
insulin debinding buffer prior to glucose transport assays. 
The cells were then washed once with PBS (pH 7.4), followed 
by a 15-minute incubation in a 22° c environmental shaker in 
1 ml assay media (1 packet of Sigma DMEM base, 10 ml lOOmM 
sodium pyruvate, 3.1 ml 0.5% phenol red, 5.96 g HEPES, 0.42 
g sodium bicarbonate, 10 ml 200mM glutamine, 1 L pyrogen-
free water, 0.1% BSA, pH 7.4) per well containing increasing 
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amounts of insulin ( o, 1x10-10 M, 1x10-9 M, 1x10-s M, 1x10-7 M, 
lxl0-6 M; or o, 1x10-11 M lxl0-10 M, 1x10-9 M, lxl0-8 M, 1x10-7 M) 
for each group of three wells. 100 µl 14C-deoxyglucose was 
then added for a final concentration of 0.5 µCi/ml, and the 
cells were incubated for an additional 15 minutes. The 
cells were then washed three times in ice-cold PBS (pH 7.4) 
containing 10 mM glucose, 0.9 ml 0.5 N NaOH was added to 
each well, and the plates were incubated at 37° for 30 
minutes. These cell lysates were then removed to 18 ml 
liquid scintillation vials, and 105 µl of glacial acetic 
acid plus 10 ml of Beckman Ready Value Scintillation Fluid 
(Beckman, Inc. Fullerton, CA) was added prior to reading the 
amount of 14C-deoxyglucose uptake on a Beckman LS5801 liquid 
scintillation counter. This insulin dose response curve was 
performed with each 3T3-Ll experiment to be certain that the 
high insulin/high glucose pre-incubation made the cells 
insulin resistant, and also to ensure that the control cells 
were indeed responsive to insulin. 
RNA Preparation 
Extraction Methodology 
RNAse Inactivation of Supplies 
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Glassware. All Corex tubes (Dupont, Wilminton, DE) and 
glassware were baked at 225° C overnight to inactivate 
RNAses. 
Plasticware and water. To inactivate RNases, all pipet 
tips and aqueous solutions were treated with diethyl 
pyrocarbonate (DEPC) and autoclaved prior to use. 
Isolation of RNA from Animal Tissue 
Isolation of total RNA was performed essentially by the 
method of Chomczynski and Sacchi (120,164). Frozen tissue 
pieces of 0.1-0.4 g (liver) or 0.2-1.1 g (epididymal fat) 
were homogenized for 10 seconds with a Tekmar Tissuemizer 
(Cincinnati, OH) in 5 ml of ice-cold RNA homogenization 
buffer (4 M guanidinium thiocyanate, 22 mM sodium citrate, 
0.5% Sarkosyl, and 0.1 M 2-mercaptoethanol) in a 15 ml 
polystyrene Falcon tube (Becton Dickinson Labware, Franklin 
Lakes, NJ). Following homogenization, samples were 
centrifuged at 8000 x g at 4° C for 15 minutes in a Sorvall 
RC2B high speed centrifuge (Dupont, Wilmington, DE). The 
infranatants from this spin, between the cell debris and the 
uppermost lipid layer, were then transferred to a Corex tube 
and mixed vigorously with 0.5 ml 2 M NaOAc (pH 4.0), 5 ml 
phenol, and 1 ml chloroform:isoamyl alcohol (49:1), followed 
by an incubation on ice for 15 minutes. Samples were then 
centrifuged at 8000 x g at 4° C for 30 minutes, the top 
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aqueous fraction was transferred to another Corex tube, and 
an equal volume (4 ml) of isopropanol was added. Samples 
were mixed thoroughly, then incubated for 2 hr at -70° c. 
Following this precipitation, the samples were spun at 8000 
x g at 4° c for 45 minutes. The supernatant was poured off, 
the pellet was resuspended in 1 ml of RNA homogenization 
buffer, and 100 µl of 3 M NaOAc (one tenth volume) plus 1 ml 
isopropanol (equal volume) were added to the samples. 
Following another 2 hr incubation at -70° c, the samples 
were spun for 45 minutes at 8000 x g and 4° C to precipitate 
the RNA. The supernatant was then poured off and the pellet 
was washed with 1 ml of 70% ethanol followed by a 3 minute 
spin at 8000 x g at 4° c. The ethanol supernatants were 
poured off, the pellets were allowed to dry, and then the 
RNA samples were resuspended in 0.2-1 ml DEPC-treated water. 
Samples were stored at -70° c. 
Isolation of RNA from 3T3-Ll Cells 
Two lOOmm plates of differentiated, pretreated 3T3-Ll 
cells were combined for each data point. The prefeed media 
was aspirated, the cells were washed once with PBS, and then 
5 ml of RNA homogenization buffer was split between the two 
plates. Cells were scraped from the two plates with a 
sterile rubber policeman and combined into a Corex tube. To 
ensure that the cells were lysed, the samples were pipetted 
up and down in a 10 ml pipette 5 times. From this point on, 
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the samples were treated exactly as the infranatants from 
the first spin in the animal tissue extractions as described 
above. 
Concentration Determination 
The UV absorbance of the RNA sample was read at 260A on 
a Beckman DU-64 Spectrophotometer (Beckman Instruments, 
Inc., Arlington Heights, IL) using the Nucleic Acid Soft-Pac 
Module software(Beckman Instruments, Inc.). The conversion 
factor used to determine the concentration of the RNA 
samples was 1 Optical Density unit = 40 µg/ml. 
Northern Blot Analysis 
Electrophoresis 
Electrophoresis was performed essentially by the method 
of Fourney, et al. (165). 10 µg of total RNA at a 
concentration of 1 µg/µl in RNA loading buffer (0.04 mg/ml 
ethidium bromide, 53% formamide, 17% formaldehyde, 7% 
glycerol, and 5.6% saturated bromophenol blue in lx 3-[N-
morpholino]propanesulfonic acid (MOPS)) was loaded per lane 
on 1.1% agarose gels. An RNA ladder was run on each gel to 
ensure that the band resulting from hybridization was the 
correct transcript size, and also to maintain the correct 
orientation of the samples. The gels were electrophoresed 
at 90V for 4 hours in lX MOPS (0.02 M MOPS, 5 mM NaOAc, 1 mM 
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EDTA, pH 7.0), after which the gels were washed twice in lOX 
SSC (1.5 M NaCl, 0.15 M citrate, pH 7.0) at room temperature 
for 20 minutes. 
Transfer of RNA to a Membrane by Northern Blotting 
Following the two lOX SSC washes described above, the 
RNA was transferred overnight by capillary action to a 
Nytran nylon membrane (Schleicher and Schuell, Keene, NJ) by 
the method of Fourney and coworkers (165). The RNA was then 
UV crosslinked to the membrane using a Stratagene UV 
Stratalinker™ 1800 (Stratagene, La Jolla, CA). The nylon 
membranes were then placed on a UV transilluminator and 
photographed with a Polaroid MP-3 Land Camera, with an 
orange filter and Polaroid Type55 positive/negative black 
and white film. Exposure was for 25 seconds, with an 
aperture seting of f/8, followed by a 20 second development. 
Loading Correction 
Loading correction for RNA blots was based on the 
amount of 28S ribosomal RNA per lane, as measured by 2-
dimensional densitometric analysis of the negative from the 
photograph of the northern blot. The 28S signal on the 
negative from the amount of RNA loaded per lane (10 µg) was 
determined to be in the linear range of the film under our 
photographic conditions, as determined by Bonini and Hofmann 
( 166) . 
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Riboprobe Preparation and Hybridization 
DNA Template Preparation 
ONA templates for Riboprobe preparation were isolated 
from bacterial slushes containing the appropriate plasmid 
using the QIAGEN kit {Chatsworth, CA). Ten µl of the 
appropriate bacterial slush stock (which has an OD of 1.0 
when read at 600A with a spectrophotometer) was used to 
inoculate 200 ml of Luria-Bertani broth with 150 µg/ml 
ampicillin. The culture was grown overnight to a 
concentration of cells which had an optical density of 1.0 
when read at 600A. The 200 ml culture was then split into 
four 50 ml conical centrifuge tubes in equal aliquots and 
centrifuged at 1000 rpm at 4°C in a table-top Sorvall 
RT6000B. The supernatant was discarded, and each pellet was 
resuspended in 10 ml Pl buffer {100 µg/ml RNAse A, 50 mM 
Tris/HCl, and 10 mM EDTA pH 8.0). Ten ml of P2 buffer {200 
mM NaOH, 1% SOS) was added to the samples, and after a 
gentle shaking, the samples were incubated for 5 minutes at 
room temperature. Ten ml of P3 was added, the samples were 
gently mixed, incubated on ice for 20 minutes, and then spun 
at 10,000 x g for 30 min. The supernatant was then passed 
through a cell strainer (Beckton Dickinson Labware, Franklin 
Lakes, NJ) into the Qiagen Q500 column, which was pre-
equilibrated with 10 ml of QBT buffer (750 mM NaCl, 50 mM 
MOPS, 15% ethanol, pH 7.0, and 0.15% Triton X-100). ·The 
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column was then washed with 30 ml of buffer QC (1.0 M NaCl, 
50 mM MOPS, 15% ethanol, pH 7.0), followed by elution with 
15 ml buffer QF (1.25 M NaCl, 50 mM MOPS, 15% ethanol, pH 
8.2). The DNA samples were then precipitated with 0.7 
volume of isopropanol, spun at 16,000 x g for 30 minutes at 
room temperature, washed with 70% ethanol, and resuspended 
in 50 µl TE (10 mM Tris-Cl, pH 7.4, 1 mM EDTA, pH 8.0). The 
concentration of the purified plasmid was determined by 
reading the absorbance of the sample at 260A. The 
conversion factor used to determine the concentration of the 
DNA was 1 OD unit equals a concentration of 50 µg/ml. DNA 
templates were then linearized using 0.5 µg/µl DNA, 20 units 
restriction enzyme, 4 µl lOX REACT Buffer, and 12 µl DEPC-
H20). 
Probe Preparation 
32P-labeled Riboprobes were prepared according to the 
recomendations of the supplier (Promega, Madison, WI). 
Linearized DNA was incubated with the transcription reagents 
(1.2 mM ATP, 1.2 mM GTP, 1.2 mM UTP, 10 mM OTT, 25 units/µl 
RNAsin, lX transcription buffer, 5 µM CTP, 5-10 units T7 RNA 
polymerase, and 50 µCi of a-32P-CTP) for 1 hour at 37° c, 
after which RNAse-free DNAse (lU/µl) was added, and the 
probes were incubated for an additional 15 minutes to remove 
any remaining template. Riboprobes were then subjected to a 
phenol-chloroform extraction and precipitated with 1/10 
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volume NaOAc and 2.5 volumes of 100% ethanol by incubation 
for 1-2 hours -70° c. The supernatant was poured off, the 
pellet was resuspended in 50 µl TE, and then the probe was 
passed over a 5 Prime-3 Prime column (Westchester, PA). The 
effluent from a 4 minute spin at 1670 x g through this 
column was used as the purified 32P-labeled Riboprobe for 
hybridization. 
Hybridization 
Hybridization of Riboprobes to the Nytran-bound RNA was 
performed as previously described (18). Nytran membranes 
were pre-wet in 2X SSC prior to prehybridization for 2 hours 
at 65° c with 10 ml hybridization buffer (4X SSPE, 50% 
formamide, 10% dextran sulfate, 5X Denhart's solution, 0.1% 
SDS, and 0.1 mg/ml soncated denatured salmon sperm DNA) in a 
Hybaid Mini Hybridization oven (Hybaid, Middlesex, UK). 
lOOX Denhart's (2% polyvinylpyrrolidone, 2% BSA, 2% Ficoll) 
and 2 OX SSPE ( 3 M NaCl, 0. 1 7 M NaH2P04 • H20, 0. 02 M EDTA) were 
used as stock solutions to make the hybridization buffer. 
Following prehybridization, 32P-labeled Riboprobes were 
denatured by boiling for 5 minutes with an additional 1 mg 
of denatured sonicated salmon sperm DNA, and added to the 
hybridization buffer for an overnight hybridization (16-18 
hours) in the Hybaid oven. After the hybridization, 
northern blots were washed twice at room temperature for 5 
minutes (2X SSC, 0.1% SDS), twice at 70° C (2X SSC, 0.1% 
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SOS) for 30 minutes, and twice at 70° C in O.lX SSC, 0.1% 
sos for 30 minutes. Blots were then either filmed with 
Amersham Hyperfilm MP (Arlington Heights, IL) at -70° c with 
an intensifying screen for 16-72 hours, or washed further 
with 100 ml of 2X SSC containing 3 µg/ml RNAse A and 0.005 




Total protein was prepared from animal tissue by an 
adaptation of the method previously described by Rice, et 
al. (84). Liver and epididymal fat tissue pieces of 0.1-1.2 
g were homogenized with a Tekmar Tissuemizer (Cincinnati, 
OH) in 3 ml of ice cold homogenization buffer (0.02 M Tris 
base, 0.15 M NaCl, 1% Triton X-100, 0.03 M Na4P20 7•10 H20, 1 
mM Na3V04 , 10 µM E-64, 1 mM PMSF, 3 mM EOTA, 50 µM leupeptin, 
and 10 µg/ml aprotinin). Cell lysates were then centrifuged 
at 30,000 x g for 30 minutes at 4° C, and the infranatant 
was passed through a Millex AP20 syringe filter (Millipore 
Corp., Bedford, MA) to remove any remaining lipids. 
Concentration determinations were made, sample aliquots were 
taken for immunoprecipitation or dilution in Laemmli buffer, 
and the samples were stored at -70° c. 
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3T3-Ll Cells 
Four lOOmm plates of confluent, differentiated, prefed 
3T3-Ll adipocytes were used per data point. One ml of ice-
cold homogenization buffer was added to each plate, the 
cells were scraped with a rubber policeman, and pipetted up 
and down repeatedly to ensure cell lysis. The lysates from 
the four plates were then combined into one tube, 
centrifuged at 30,000 x g for 30 minutes at 4° c, and passed 
through a Millex AP20 syringe filter. Samples were stored 
at -70° c. 
Isolated Mouse Adipocytes 
Equal amounts of isolated mouse adipocytes were 
homogenized in 500 µl of ice-cold homogenization buff er 
using a tef lon Dounce homogenizer connected to a Glas-Col 
variable speed laboratory motor (Terre-Haute, IN) at speed 2 
for 10 seconds, followed by centrifugation at 16,000 x g for 
30 minutes. The infranatant was passed through a Millex AP4 
syringe filter, and the samples were then stored at -70° c. 
Concentration Determination 
The concentration of each protein sample was determined 
the day of the experiment, and sample aliquots were taken 
for immunoprecipitation and SDS-polyacrylamide gel 
electrophoresis. Concentrations were determined by the 
Lowry method (167) using the BioRad De Assay (Bio-Rad, 
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Hercules, CA). The absorbance of the samples at 750A was 
compared against a standard curve of varying concentrations 
of BSA in homogenization buffer. 
Immunoprecipitation 
Sample and Antibody Concentrations 
For immunoprecipitation of IRS-1 from isolated primary 
adipocytes, 1 mg total protein in 500 µl was incubated with 
8 µg anti-IRS-1 antibody (Upstate Biotechnologies, Inc.). 
For immunoprecipitation of IRS-1 from animal tissue, 10 µl 
of the anti-baculovirus IRS-1 antibody was added to 1 mg 
total protein in 400 µl, as recommended by the supplier 
(Morris White, Boston, MA). 
Methodology 
Cell lysates were incubated with anti-IRS-1 antibodies 
overnight (16-18 hours) at 4° c with gentle rocking. 
Following the overnight incubation, 100 µl of protein A-
Sepharose (Pharmacia, Milwaukee, WI) was added and the 
samples were rocked for an additional 2 hours at 4° c. The 
samples were then centrifuged at 16,000 x g for 2 minutes, 
and the pellets were washed twice with 1 ml wash buffer (140 
mM NaCl, 2.7 mM KCl, 10 mM Na2HP04 1.8 mM KH2P04 , 100 µM 
Na3V04 , and 1% NP40), with a 2 minute centrifugation at 
16,000 x g between washes. After the second wash, the 
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pellet was resuspended in 100 µl of 2X Laemmli Sample 
Buffer(lX = 62.5 mM Tris, 10% glycerol, 2% sos, 10% 2-
mercaptoethanol, and .001% bromophenol blue) and boiled for 
6 minutes prior to electrophoresis. 
Western Blot Analysis 
SOS-PAGE 
Total cell lysates in lX Laemmli sample buffer or 
immunoprecipitates were electrophoresed on 7.5% or 12% 
polyacrylamide gels essentially according to the method of 
Laemmli (168). Equal amounts of protein (between 10 and 30 
µg for total lysates) or equal volumes of immunoprecipitate 
were electrophoresed on duplicate gels at 150 V for 1.5 
hours using the Bio-Rad Mini-Protean II Dual Slab Cell (Bio-
Rad, Richmond, CA). On each gel a molecular weight marker 
(Bio-Rad, Richmond, CA) was included for orientation and 
size determination purposes. Where appropriate, a positive 
control for IRS-1 or PI3K p85a was used to confirm that the 
correct protein was visualized during immunostaining. 
Proteins were then electrophoretically transferred to 
Immobilon P membranes (Millipore Corp., Bedford, MA) using 
the Bio-Rad Mini-Transblot electrophoretic transfer cell 
(Bio-Rad, Richmond, CA) for 3-4 hours at 100 v. One set of 
the duplicate blots was used for Coomassie staining, 
followed by total protein quantitation of the stained blot. 
This quantitation was used for normalizing for differences 
in loading between lanes. The other set of blots was 




Western blots were blocked 2 hours or overnight in 
Tris-Buffered Saline (TBS = 0.9% NaCl, 20 mM Tris, pH 7.4) 
with 5% BSA, then washed four times for 10 minutes with TBS-
tween (TBST) wash buffer (TBS, 0.05% Tween-20, 0.1% BSA) and 
incubated with primary antibody for 2 hours in antibody 
dilution buffer (TBS, 0.05% Tween-20, 1% BSA). Blots with 
mouse tissue anti-IRS-1 immunoprecipitates were probed with 
the monoclonal anti-IRS-1 antibody and required an overnight 
incubation with the primary antibody. Following the primary 
antibody incubation, the blots were washed four times for 10 
minutes in TBST, then incubated for 30 minutes in antibody 
dilution buffer with the appropriate secondary antibody. 
After the incubation with the secondary antibody, the blots 
were washed four times for 15 minutes in TBST before 
exposure to the ECL reagents for 1 minute. The excess ECL 
liquid was allowed to drain off, and the blots were placed 
between two sheets of acetate and exposed to Hyperf ilm MP or 
Hyperfilm ECL for a period of 10 seconds to 45 minutes. 
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Primary antibody dilutions. The anti-IR ~-subunit 
antibody was used at a 1:2000 dilution. The anti-IRS-1 
monoclonal antibody and anti-phosphotyrosine antibody were 
used at a 1:1000 dilution, and the anti-IRS-1 c-terminal 
polyclonal antibody was used at a 1:1500 dilution. Both 
anti-PI3K p85a antibodies were used at a dilution of 1:8000. 
Anti-GRB2, anti-Nck, and anti-Syp antibodies were used at a 
1:4000 dilution. 
Secondary antibody dilutions. The anti-mouse HRP-
linked secondary antibody was used at a dilution of 1:7500. 
The anti-rabbit HRP-linked secondary antibody was used at a 
1:6000 dilution. 
Image Analysis 
All autoradiographs from northern blots and ECL western 
blots were quantitated by video densitometry using the Ambis 
Image Acquisition Analysis system (San Diego, CA). This 
system was also used for determination of molecular weights 
of proteins and sizing of mRNA transcripts by comparison of 
sample lanes with molecular weight lanes or RNA ladder 
lanes. 
Statistics 
All data were analyzed for statistical significance 





For most experiments with two groups, such as the rat 
experiments (control vs. streptozotocin-treated) or the 3T3-
Ll cell culture experiments (low glucose/no insulin vs. high 
glucose/high insulin), the data was analyzed with an 
unpaired Student's T-Test using a two-sided p-value. A p-
value less than 0.05 was considered significant. 
Nonparametric Test 
For two-group experiments in which the standard 
deviations were significantly different between groups and 
were also not normalized by log, square-root, or reciprocal 
transformation of the data, the Mann-Whitney nonparametric 
test with a two-sided p-value was used to analyze the data. 
A p-value less than 0.05 was considered significant. 
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Experiments with More Than Two Groups 
Ordinary ANOVA 
In most experiments with more than two groups, such as 
the mouse, primary adipocyte, or 3T3-Ll acute insulin 
studies, the data was analyzed using ANOVA with the Tukey 
multiple comparisons post-test. A p-value of less than 0.05 
was considered significant. 
Kruskal-Wallace Nonparametric Test 
For experiments with more than two groups in which the 
standard deviations were significantly different between 
g~oups and were also not normalized by log, square-root, or 
reciprocal transformation of the data, the Kruskal-Wallace 
nonparametric test with the Dunn's multiple comparisons test 




Glycemic State and Insulin Levels of KKAY Mice 
The blood glucose and serum insulin levels were 
determined from blood samples taken from the animals at the 
time of tissue extraction at The Upjohn Company. The blood 
glucose level for the control C57 mice was 170±6 mg/dl or 
9.4±0.3 mM (±SEM), while the average blood glucose level in 
KKAY mice was 494±25 mg/dl or 27.4±1.3 mM. Pioglitazone 
treatment of KKAY mice lowered the blood glucose level to 
257.4±18.3 mg/dl (14.3±1.0 mM). 
Serum insulin levels were similarly elevated in the 
KKAY mice as compared to control C57 mice, and these levels 
were also partially corrected by pioglitazone treatment. 
C57 mice had an average serum insulin concentration of 
25. 8±2. 7 µU/ml or 1. 9x10-10±0. 2x10-10 M (±SEM), while the 
average serum insulin level of KKAY mice was 476.9±54.4 
µU/ml or 3. 5x10-9±o. 4x10-9 M. Pioglitazone treatment of KKAY 
mice corrected the average serum insulin levels to 
299.5±33.2 µU/ml (2.2X10~±0.2x10~ M). 
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Expression of Insulin Signaling Components in Animal NIDDM 
The expression of the insulin receptor (IR), IRS-1, 
PI3K p85a, GRB2, Nck, and Syp was analyzed in three animal 
groups: C57 control mice (C), KKAY diabetic mice (D), and 
KKAY mice treated with pioglitazone (D+P) • The observed 
protein and transcript sizes are shown in table 1. All data 
in figs. 2 and 3 are expressed as percent of control C57 
expression for each group, ± standard error of the mean 
(SEM). 
Protein Levels of Insulin Signal Components 
In order to determine if the protein levels of IR, IRS-
1, p85a, GRB2, Nck and Syp were altered in insulin resistant 
animals as compared to control nondiabetic animals, and to 
determine if pioglitazone treatment corrected these 
alterations, protein extracts of epididymal fat and liver 
tissue from nondiabetic C57 mice, obese KKAY insulin-
resistant mice, and KKAY mice treated with pioglitazone were 
analyzed by western blotting. The abundance of the proteins 
studied was determined to be roughly the same between liver 
and adipose in the control animals. 
Table 1.-- Observed Protein and mRNA Transcript Sizes of 
Signaling Components 
Protein size mRNA size 
Gene (kDa) (kb) 
IR 96.5 9.5, 7.5 
IRS-1 162.9 9.5 




The Insulin Receptor 
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In both epididymal fat and liver, the IR levels in KKAY 
mice were reduced to 17±3% and 33±4% of C57 control levels, 
respectively, and these were increased significantly with 
pioglitazone treatment to 32±3% and 57±5% of control levels 
(fig. 2, upper panels). 
IRS-1 
IRS-1 protein levels were not significantly different 
between C57 and KKAY mice, and pioglitazone treatment did 
not significantly alter IRS-1 protein abundance in either 
tissue (fig. 2, middle panels). 
PI3K p85a 
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The expression of PI3K p85a was measured using a 
monoclonal antibody directed against the SH2 domains of 
p85a. As seen in fig. 2, two major bands of approximately 
the same size are recognized by this antibody in fat tissue. 
This may be due to cross-reactivity with another protein, 
p87~, which has high homology to p85a (128). While both 
proteins may associate with the pllO subunit (128), we found 
that only the lower band (p85a) associated with IRS-1 on 
insulin stimulation of isolated adipocytes (fig. 11). In 
addition, the lower band lined up with the baculovirus-
expressed p85a positive control, while the upper band did 
not. Also, the recent availability of an antibody specific 
for the SH3 domains of only p85a detected only the lower of 
the two bands in fat tissue (data not shown). For these 
reasons, the lower band observed in fat tissue was 
quantitated as p85a. 
PI3K p85a protein levels were significantly lower in 
KKAY fat (47±3 % of control) and fully corrected by 
pioglitazone administration to 103±15% of control levels 
(fig 2, panel E). However, p85a levels in liver were not 
significantly different between C57 and KKAY mice, and were 
not altered by pioglitazone treatment (fig. 2, panel F). 














Fig. 2. The protein levels of the insulin receptor (IR), 
IRS-1, and PI3K p85a are depicted in C57 (C), KKAY (D), and 
KKAY + pioglitazone (D+P) as% Control C57, with fat data on 
the left and liver data on the right. Inside each graph is 
a representative western blot for the respective protein, 
shown with an n=3 for c, D, and D+P. The upper panels 
represent protein levels of IR, the center panels represent 
the protein levels of IRS-1, and the lower panels show the 
protein levels for PI3K p85a. For all experiments, n=12 and 
all values represent the mean ± SEM (* indicates p<0.-05, ** 
indicates p<0.01, and*** indicates p<.001). 
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Pioglitazone treatment did not significantly alter the 
expression of the insulin receptor, IRS-1, or p85a proteins 
in the control animals (data not shown). 
GRB2, Nck, and Syp 
GRB2, Nck, and Syp levels were regulated in an opposite 
manner from IR, IRS-1, and p85a levels. 
GRB2. GRB2 protein abundance was significantly 
elevated in KKAY epididymal fat (321±25% control - fig. 3, 
panel A). In liver tissue this elevation was not as great 
(118±6% control), although it was significant (fig 3, panel 
B). Pioglitazone administration did not alter GRB2 levels 
to a large extent, but it did lower the slightly elevated 
KKAY liver GRB2 levels to control levels. 
Nck. Like GRB2, Nck levels were much higher in KKAY 
fat as compared to C57 (186±12% control), and there was a 
smaller but significant elevation of Nck in KKAY liver 
compared to C57 (124±7% control - fig. 3, middle panels). 
Again, there was little effect of pioglitazone treatment on 
Nck protein levels in the treated KKAYtissues. 
~ Syp protein levels were 43±11% higher in KKAY fat 
than in C57, and 25±4% higher in KKAY liver compared to C57. 
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Fig. 3. The protein levels of the GRB2, Nck, and Syp are 
depicted in C57 (C), KKAY (D), and KKAY + pioglitazone (D+P) 
as% Control C57, with fat data on the left and liver data 
on the right. Inside each graph is a representative western 
blot for the respective protein, shown with an n=3 for c, D, 
and D+P. The upper panels represent the protein levels of 
GRB2, the center panels represent the protein levels of Nck, 
and the lower panels show the protein levels for Syp. For 
all experiments, n=12 and all values represent the mean ± 
SEM (* indicates p<0.05, ** indicates p<0.01, and *** 
indicates p<.001). 
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(p<0.05). Pioglitazone treatment did not significantly 
change Syp levels in fat, but it did lower liver syp levels 
in liver tissue toward control levels (fig. 3, lower 
panels). Pioglitazone treatment did not significantly alter 
the expression of GRB2, Nck, or Syp in control animals (data 
not shown). 
mRNA Levels of Insulin Signaling Components 
PI3K has been implicated in insulin stimulated glucose 
transport (99,102), and KKAY mice display a defect in 
insulin's ability to promote glucose uptake in fat and 
muscle (18). Therefore, potential mechanisms for lowered 
levels of IR and p85a proteins were determined by analyzing 
the mRNA abundance of these transcripts in tissues of 
nondiabetic C57 mice, obese KKAY insulin-resistant mice, and 
KKAY mice treated with pioglitazone. IRS-1 mRNA abundance 
was also determined in the same groups. A northern blot for 
the insulin receptor showed transcripts of two lengths: 9.5 
kb and 7.5 kb. The difference in size between these two 
transcripts results from differential poly-A site selection 
and there is no known functional difference between the 9.5 
and 7.5 kb transcripts (59). The IRS-1 mRNA transcript is 
9.5 kb long, and the primary p85a mRNA size is 7.5 kb. The 
abundance of these transcripts was determined as described 
in Materials and Methods above. Data are summarized in 
figures 4, 5, and 6. 
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Insulin Receptor 
In epididymal fat and liver, receptor mRNA levels were 
slightly less in the KKAY mice as compared to C57, although 
the only significant difference was in the liver with the 
7.5 kb transcript (figure 4). Pioglitazone administration 
did not have a significant effect on receptor mRNA levels. 
There was no detectible difference in the 9.5/7.5 kb ratio 
between any of the groups. 
IRS-1 
IRS-1 mRNA levels were significantly lower in KKAYfat 
and liver (53.3±4.3 and 50.7±6.2% control, respectively) 
than in the C57 controls, with no correction by pioglitazone 
treatment (figure 5). However, this difference in IRS-1 
mRNA abundance was not associated with a significant change 
in the IRS-1 protein levels (fig. 2, middle panels). 
PI3K p85a 
In epididymal fat, p85a mRNA abundance was not 
significantly different between the C57 and KKAY mice, 
although the mean p85a mRNA level was 75% of control. 
Pioglitazone treatment did not significantly alter the p85a 
mRNA levels in the treated KKAY group as compared to the 
untreated KKAY group (fig. 6). The mRNA levels of p85a were 
not determined in liver because there was no difference in 
the level of p85a protein in this tissue. 
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Fig. 4. The mRNA levels for the insulin receptor in C57 
(C), KKAY (D), and KKAY + pioglitazone (D+P) are depicted as 
mean% control C57, ± SEM. Left, IR RNA abundance in fat; 
right, IR RNA in liver. Solid bars represent the abundance 
of the 9.5 kb receptor transcripts and hatched bars 
represent the 7.5 kb transcript abundance. n=12 for both 
fat and liver data. * represents a statistical difference 
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Fig. 5. The mRNA levels for IRS-1 in C57 {C), KKAY (D), and 
KKAY + pioglitazone (D+P) are depicted as mean % control 
C57, ± SEM. Left, IRS-1 RNA abundance in fat; right, IRS-1 
RNA in liver. n=12 for both tissues, and * represents a 
statistical difference with a p value less than 0.05 

















Fig. 6. The levels of mRNA transcripts PI3K p85a in 
epididymal fat from C57 (C), KKAY (D), and KKAY + 
pioglitazone (D+P) are depicted as mean% control C57, ± 
SEM. n=12 for both tissues, and * represents a statistical 
difference with a p value less than 0.05 relative to 
control. 
79 
GRB2. Nck, and Syp 
The cDNA for GRB2, Nck, and Syp were not available at 
the time of the study; thus, the RNA levels for these 
components in this model are unknown. Since the differences 
in GRB2 and Nck protein levels between C57 and KKAY mice 
were very large, in the future it would be interesting to 
determine if such differences also exist at the RNA level. 
Function of the Insulin Receptor and IRS-1 in Animal NIDDM 
Insulin-Stimulated Tyrosine Phosphorylation 
of the Insulin Receptor And IRS-1 
In order to study the role of insulin receptor function 
in insulin resistance, primary adipocytes were isolated from 
epididymal fat of C57 mice, KKAY mice, and KKAY mice 
pretreated with pioglitazone. These adipocytes were then 
stimulated acutely with insulin, and the tyrosine 
phosphorylation of the insulin receptor ~ subunit and IRS-1 
was assayed by western blotting with an anti-phosphotyrosine 
antibody. A representative blot is shown in fig. 7, and the 
graphed results of the cumulative data are illustrated 
in figures 8, 9, and 10. Although the representative blot 
shows an n of 2, The n for these experiments was 10 cell 
aliquots per group. The data are represented as the percent 
phosphorylation of the unstimulated C57 control group, ± 
SEM. 
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Insulin Receptor Phosphorylation 
In control C57 mice, acute insulin stimulation resulted 
in an 11.4-fold increase in insulin receptor ~ subunit 
tyrosine autophosphorylation (fig. 8). In adipocytes from 
KKAY mice, insulin stimulation failed to increase the 
tyrosine phosphorylation of the insulin receptor relative to 
the KKAY basal tyrosine phosphorylation, and the receptor 
was not made any more sensitive to insulin in stimulating 
tyrosine phosphorylation of its ~ subunit by prior 
pioglitazone treatment of the mice (fig. 8). Also, basal 
phosphorylation of the receptor in KKAY mouse adipocytes was 
significantly higher (about 6-fold) than basal tyrosine 
phosphorylation of the receptor in C57 mice. This is likely 
due to the higher level of circulating insulin in the KKAY 
mice relative to the control mice. Pioglitazone treatment 
did not significantly lower the basal phosphorylation of 
KKAY insulin receptors. Therefore, there appears to be both 
a decreased number of receptors (fig. 2) and a decrease in 
the responsiveness of the receptors to insulin in KKAY mice. 
Because pioglitazone treatment partially corrects 
receptor number back toward control levels, the mean 
phosphorylation per unit receptor appears to be lowered to 
approximately a third of the phosphorylation per receptor in 
untreated KKAY mice (fig.9), although this change was not 
quite significant (p=0.0594). However, the analysis of the 
data as phosphorylation per receptor did emphasize the 
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Fig. 7. Phosphotyrosine content of the insulin receptor 
(IR) and IRS-1 was detected by western blotting with anti-
phosphotyros ine antibodies of lysates from isolated 
adipocytes unstimulated or stimulated acutely with 100 nM 
insulin for 2 minutes. This representative blot shows an 
n=2 for each group: D=KKN (unstimulated), D/I=KKAY 
(stimulated) , D/P=KKAY pretreated with pioglitazone 
(unstimulated), D/P/I=KKAY pretreated with pioglitazone 
(stimulated), C=C57 (unstimulated), C/I=C57 (stimulated). 



































Fig. 8. cumulative graphed results of acute insulin-
stimulated phosphorylation of the insulin receptor ~ subunit 
in isolated adipocytes are depicted as mean % unstimulated 
control (C57) ± SEM, n=lO. Data were accumulated from anti-
phosphotyrosine western blots such as is shown in fig. 7. 
*** represents a statistical difference (p<0.001) between 



























Fig. 9. Cumulative graphed results of receptor tyrosine 
phosphorylation per unit receptor in isolated adipocytes are 
depicted as mean % unstimulated control (C57) ± SEM, n=lO. 
Data were accumulated from anti-phosphotyrosine western 
blots such as is shown in fig. 7 and anti-IR~ western blots 
of the same samples. *** represents a statistical 
























Fig. 10. cumulative graphed results of acute insulin-
stimulated phosphorylation of IRS-1 in isolated adipocytes 
are depicted as mean % unstimulated control (C57) ± SEM, 
n=lO. Data were accumulated from anti-phosphotyrosine 
western blots such as is shown in fig. 7. * represents a 
statistical difference (p<0.05) as compared to the 
unstimulated control group. 
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increased basal phosphorylation of the receptor in the KKAY 
mice as compared to control. 
IRS-1 Phosphorylation 
The insulin-stimulated tyrosine phosphorylation of IRS-
1 in control mice was not as pronounced as that of the 
insulin receptor (fig. 7 and fig. 10). Insulin stimulation 
of the control isolated adipocytes caused an increase in 
tyrosine phosphorylation of IRS-1 by 72.4±21.1% over 
nonstimulated cells (fig. 10), while in KKAY adipocytes 
insulin failed to stimulate tyrosine phosphorylation over 
the nonstimulated KKAY adipocytes. As with the insulin 
receptor phosphorylation, pioglitazone treatment did not 
make the KKAY cells any more sensitive to insulin in 
phosphorylating IRS-1. In contrast to receptor 
phosphorylation, the basal tyrosine phosphorylation of IRS-1 
in KKAY adipocytes or pioglitazone-treated KKAY adipocytes 
was not elevated relative to the IRS-1 tyrosine 
phosphorylation in unstimulated C57 adipocytes (fig. 10). 
The IRS-1 phosphorylation per unit IRS-1 was not determined 
since there was not a significant difference in IRS-1 
protein levels between the three groups. 
Insulin-Stimulated Association of IRS-1 
with PI3K p85a 
86 
Following insulin stimulation of the receptor tyrosine 
kinase and tyrosine phosphorylation of IRS-1, IRS-1 is known 
to associate with PI3K p85a via the phosphorylated YMXM 
motifs on IRS-1 and the SH2 domains of p85a. Therefore, the 
association of IRS-1 with p85a on insulin stimulation was 
compared between C57 and KKAY mice. Since pioglitazone 
partially corrects blood glucose levels, and PI3K has been 
linked to glucose transport, the KKAY mice treated with 
pioglitazone were included in this comparison. In addition, 
as is shown in figure 2, pioglitazone corrected PI3K p85a 
protein levels in epididymal fat to C57 levels and thus may 
result in increasing the association of PI3K p85a with IRS-
1. 
However, given the above results from figures 7 and 10, 
one would expect that in the absence of insulin-stimulated 
IRS-1 phosphorylation in KKAY mice or pioglitazone-treated 
KKAY mice, there would be no insulin stimulation of p85a 
associated with IRS-1 in either group. To determine if the 
pioglitazone correction of PI3K p85a levels resulted in a 
correction of insulin signaling at this level, lysates from 
the isolated adipocytes from C57, KKAY, and pioglitazone-
treated KKAY mice with or without acute insulin stimulation 
were subjected to an immunoprecipitation with a polyclonal 
anti-IRS-1 antibody. These immunoprecipitates were then 
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size-fractionated on SOS-PAGE and immunoblotted for PI3K 
p85a to observe the amount of p85a which associates with 
IRS-1 on insulin stimulation in each group. A 
representative blot is shown in fig. 11, and the cumulative 
data from an n of 10 are summarized in fig. 12. As is 
shown in fig. 12, acute insulin stimulation of C57 
adipocytes caused p85a to associate with IRS-1 to a level of 
217.2±25.8% of the amount of p85a associated with IRS-1 in 
unstimulated control cells. Like the tyrosine 
phosphorylation of IRS-1, the basal association of p85a with 
IRS-1 in KKAY and pioglitazone-treated KKAY groups was about 
the same as the basal level in unstimulated C57 adipocytes, 
and this association was not elevated by insulin 
stimulation. 
The Effects of Insulin and Glucose on Signal Transduction 
Components 
Expression of Insulin Signaling Components in the Presence 
of High Glucose or High Glucose plus High Insulin 
To determine if the alterations in expression and 
function of insulin signaling components observed above in 
the KKAY mice was due to the presence of the high glucose 
and high insulin levels in these animals, two other models 
were used. First, differentiated 3T3-Ll adipocytes 
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pretreated with high glucose (25mM or 450mg/dl) plus high 
insulin (2 µM) medium overnight were used in an attempt to 
mimic the hyperglycemia and hyperinsulinemia of KKAY mice. 
This caused the cells to be resistant to insulin stimulation 
of glucose uptake (fig. 13). 3T3-Ll cells pretreated 
overnight in low glucose (5.5 mM or 100 mg/dl) and very low 
insulin medium were used as control cells to represent the 
normoglycemic state. 
In addition, a rat model of IDDM displaying high 
glucose (459±10 mg/dl) relative to control rats (151±2 
mg/dl) was used to determine whether the presence of high 
circulating levels of glucose in the absence of high insulin 
levels could affect the expression of these proteins. 
Streptozotocin treatment of rats induces IDDM by causing 
destruction of the pancreatic ~ cells, and in this model 
lowered blood insulin levels to roughly 20% of the insulin 
levels in the control rats (data not shown). 
3T3-Ll Cells 
In the 3T3-Ll model, the expression of all six of the 
signaling components and insulin-stimulated phosphorylation 
of the insulin receptor and IRS-1 were studied. Fig. 13 
shows the degree of insulin resistance caused by high 
insulin and glucose incubation as assayed by 14C-deoxyglucose 
uptake upon acute insulin stimulation with increasing 
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+- PI3K p85a 
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Fig. 11. The amount of PI3K p85a associating with IRS-1 was 
detected by western blotting of anti-IRS-1 
immunoprecipitates from isolated adipocytes unstimulated or 
stimulated acutely with 100 nM insulin for 2 minutes. This 
representative blot shows an n=2 for each group: D=KKAY 
(unstimulated), D/I=KKAY (stimulated), D/P=KKAY pretreated 
with pioglitazone (unstimulated), D/P/I=KKAY pretreated with 
pioglitazone (stimulated), C=C57 (unstimulated), C/I=C57 
(stimulated). MW=molecular weight markers. The two bands 
in the MW lane are 106,000 (upper band) and 80,000 (lower 
band). The lane labeled PI3K was loaded with PI3K p85a 
positive control. The labels on the right of the figure 
indicate the positions of PI3K p85a migration and the IgG 
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Fig. 12. cumulative graphed results of acute insulin-
stimulated association of PI3K p85a with IRS-1 in isolated 
adipocytes are depicted as mean % unstimulated control (C57) 
± SEM, n=lO. Data were accumulated from anti-p85a western 
blots of IRS-1 immunoprecipitates such as is shown in fig. 
11. ** represents a statistical difference (p<0.01) between 
the bracketed groups. ns=not significant (p>0.05). 
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Fig 13. Representative insulin dose-response curves are 
shown for insulin-stimulated 14C-deoxyglucose uptake in 3T3-
Ll adipocytes pre-fed overnight with DMEM containing 5.5mM 
glucose (LG,-I, thick solid line,+), 5.5mM glucose+ 
2x10~ insulin (LG,+I, thick dashed line, O), 24.4 mM 
glucose (HG,-I, thin dashed line, V), or 24.4 mM glucose+ 
2x10-6M insulin (HG,+I, thin dotted line, •). Each symbol 
represents the average amount of 14C-deoxyglucose uptake 
(n=6) at the given insulin concentration, and the lines 
represent a sigmoidal regression of each data set. 
amounts of insulin. High glucose in the absence of high 
insulin caused a decrease in the maximal insulin 
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stimulation of glucose transport, while high insulin with or 
without high glucose fully attenuated the ability of the 
cells to take up glucose on insulin stimulation. 
Insulin receptor. The expression and phosphorylation 
of the insulin receptor in insulin-resistant 3T3-Ll 
adipocytes were altered in a manner similar to theexpression 
and phosphorylation of the receptor observed in KKAY mice. 
The receptor protein levels in the insulin-resistant cells 
was lowered to 33.6±3.3% of control cell receptor expression 
(fig. 14, left panel), much like the lower expression seen 
in KKAY mice as compared to C57. The levels of 9.5 and 7.5 
kb mRNA transcripts were significantly lowered to 58.75±3.2 
and 75.3±3.6% of control cells (fig. 14, middle), a larger 
difference than was seen in the receptor RNA levels between 
the KKAY and control mice. Another interesting observation 
was that the high glucose and high insulin incubation caused 
a shift in the ratio of the 9.5 to 7.5 kb transcripts. In 
control cells, there was an 11% difference between the 
percent 9.5 kb transcript in the total receptor RNA and the 
7.5 kb transcript in the total. In the cells treated with 
high insulin and high glucose, this difference disappeared 
(fig. 14, right). 
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Fig. 14. Graphed results of the protein and RNA levels of 
the insulin receptor in 3T3-Ll cells. LG-I=3T3-Ll cells 
pre-fed overnight in low glucose (4.4 mM) DMEM; HG+I=3T3-Ll 
cells pre-fed overnight in high glucose (24.4 mM) DMEM with 
2x10·6 M insulin. Left, protein levels are represented as % 
control (LG-I) ± SEM, n=22. Center, the RNA levels are 
graphed as %control (LG-I) ± SEM for both the 9.5 and 7.5 kb 
species, n=16. The solid bar represents the amount of 9.5 
kb transcript, while the hatched bar represents the amount 
of 7.5 kb transcript. Right, the relative ratios of the 9.5 
and 7.5 kb transcripts are shown as % of the total insulin 
receptor transcripts (9.5+7.5 kb) for both treatment groups. 
* indicates a significant difference (p<0.05) as compared to 
control or between the bracketed groups. 
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The acute insulin stimulation of control 3T3-Ll cells 
resulted in a 25-fold increase in the tyrosine-
phosphorylation of the insulin receptor ~ subunit, as 
detected by western blotting with anti-phosphotyrosine 
antibodies (fig. 15). A one-minute insulin stimulation was 
used in these experiments, since the receptor and IRS-1 
tyrosine phosphorylation was maximal in control cells at one 
minute (fig. 16, lanes 4 and 5). Like the KKAY isolated 
adipocytes, the insulin-resistant cells had a much higher 
level of basal tyrosine phosphorylation than the control 
cells, and were unable to respond to insulin by further 
phosphorylation of the receptors (fig. 15, left). Likewise, 
expression of data as phosphorylation per receptor 
exaggerated the basal phosphorylation of the receptor in the 
insulin resistant cells as compared to control (fig. 15, 
right), owing to decreased receptor numbers in insulin-
treated cells. Such observations were consistent with those 
seen in adipocytes isolated from insulin-resistant KKAY mice 
(fig. 9) • 
IRS-1. The expression of IRS-1 in the insulin-
resistant 3T3-Ll cells was also regulated in much the same 
way as IRS-1 expression in KKAY mice. The protein levels of 
IRS-1 were not significantly different between control and 
insulin-resistant cells, as shown in fig. 17 (left panel). 
In addition, like in the animal model of insulin resistance, 
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Fig. 15. Cumulative graphed results of acute insulin-
stimulated phosphorylation of the insulin receptor ~ subunit 
in 3T3-Ll cells are depicted as mean % unstimulated control 
(LG-I) ± SEM, n=ll. Left, total phosphorylation of the 
insulin receptor ~ subunit as measured by western blotting 
of cell lysates with anti-phosphotyrosine antibodies. 
Right, phosphorylation per unit receptor. Solid bars 
represent unstimulated cells and hatched bars represent 
cells stimulated actuely with 1x10·7 M insulin for 1 minute. 
*** represents a statistical difference (p<0.001) between 




Fig. 16. The time course for insulin-stimulated tyrosine 
phosphorylation of IRS-1 and the insulin receptor in control 
3T3-Ll cells, as observed with western blotting with anti-
phosphotyrosine antibodies. Phosphorylated IRS-1 and IR 
bands are indicated by the arrows on the right. Lanes 1 and 
~: no insulin stimulation; lane 3: 30 second insulin 
stimulation with 1x10-7 M insulin; lanes 4 and 5: 1 minute 
insulin stimulation; lanes 6 and 7: 5 minute insulin 
stimulation; lane 8: 10 minute insulin stimulation; MW: 
molecular weight markers 205, 106, and 80 kDa from top to 
bottom. 
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the mRNA abundance for IRS-1 in the insulin-resistant 3T3-Ll 
cells was significantly lower than in the control cells 
(fig. 17, right). 
The insulin stimulated tyrosine phosphorylation of IRS-
1 was attenuated by high insulin and high glucose incubation 
of 3T3-Ll cells, as shown in fig. 18. Although this was 
also seen in the KKAY adipocytes, there was a difference 
between these two models in that the basal phosphorylation 
of IRS-1 was elevated in the in vitro model of insulin 
resistance relative to control cells (fig. 18). In the 
animals, there was not a difference in the basal tyrosine 
phosphorylation of IRS-1 between KKAY and C57 mice. Because 
there was not a large difference in the protein levels of 
IRS-1 between control 3T3-Ll cells and the insulin-resistant 
3T3-Ll cells, the results for phosphorylation per IRS-1 
(fig. 18, right) did not differ greatly from the total 
phosphorylation data (fig. 18, left). 
PI3K p85a. As in the animal epididymal fat tissue, the 
PI3K monoclonal (anti-SH2) antibody recognized two bands. 
The lower of these two bands comigrated with the 
baculovirus-produced p85a positive control on SOS-PAGE 
western blots. The expression of PI3K p85a was not altered 
by incubation of 3T3-Ll cells with high glucose and high 
insulin (fig. 19, left), although this treatment caused an 
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Fig. 17. Graphed results of the protein and RNA levels of 
IRS-1 in 3T3-Ll cells. LG-I=3T3-Ll cells pre-fed overnight 
in low glucose (4.4 mM) DMEM; HG+I=3T3-Ll cells pre-fed 
overnight in high glucose (24.4 mM) DMEM with 2x10·6 M 
insulin. Left, protein levels are represented as % control 
(LG-I) ± SEM, n=22. Right, the RNA levels are graphed as 
%control (LG-I) ± SEM, n=16. * indicates a significant 
difference (p<0.05) as compared to control. 
IRS-1 Tyrosine Phosphorylation 
















- - Ins 






















Fig. 18. Cumulative graphed results of acute insulin-
stimulated phosphorylation of IRS-1 in 3T3-Ll cells are 
depicted as mean % unstimulated control (LG-I) ± SEM, n=ll. 
Left, total phosphorylation of IRS-1 as measured by western 
blotting of cell lysates with anti-phosphotyrosine 
antibodies. Right, phosphorylation per unit IRS-1. Solid 
bars represent unstimulated cells and hatched bars represent 
cells stimulated actuely with 1x10-7 M insulin for 1 minute. 
*** represents a statistical difference (p<0.001) between 
the bracketed groups. 
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Fig. 19. Graphed results of the protein and RNA levels of 
PI3K p85a in 3T3-Ll adipocytes. LG-I=3T3-Ll cells pre-fed 
overnight in low glucose (4.4 mM) DMEM; HG+I=3T3-Ll cells 
pre-fed overnight in high glucose (24. 4 mM) DMEM with 2x10·6 
M insulin. Left, protein levels are represented as % control 
(LG-I) ± SEM, n=22. Right, the RNA levels are graphed as 
%control (LG-I) ± SEM, n=16. * indicates a significant 
difference (p<0.05) as compared to control. · 
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increase in the variance of these cells which may have 
obscured a slight increase. This differs from the mouse 
experiment, where the expression of p85a protein in KKAY 
mice was 53% lower than the expression in C57 control mice. 
Also dissimilar from the mouse experiment was that the RNA 
levels of PI3K p85a were lowered by 31±3.4% by high glucose 
and high insulin incubation of 3T3-Ll cells (fig. 19, 
right), whereas the RNA levels in KKAY fat did not differ 
significantly from the RNA levels in the control mice (fig. 
6, left), even though KKAY mice are also hyperglycemic and 
hyperinsulinemic. 
GRB2, Nck, and Syp. Incubation of 3T3-Ll cells in high 
insulin and high glucose resulted in a significant elevation 
of GRB2 and Nck protein levels, but did not change the 
expression of Syp protein (fig. 20). The elevation of these 
proteins in this model of insulin resistance is consistent 
with the higher expression of these proteins in KKAY mice as 
compared to C57 mice (fig. 3); however, the magnitude of 
these increases were much smaller in this in vitro model 
than in the in vivo model. GRB2 and Nck levels in these 
insulin-resistant 3T3-Ll cells were 135.7±8.1% and 117±3.1% 
of control, respectively, while the levels of these proteins 
in KKAY mice were 321±25.4% and 185.6±12.2% of the 
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Fig. 20. The expression of GRB2, Nck, and Syp protein in 
3T3-Ll adipocytes. LG-I=3T3-Ll cells pre-fed overnight in 
low glucose (4.4 mM) DMEM; HG+I=3T3-Ll cells pre-fed 
overnight in high glucose (24. 4 mM) DMEM with 2x10-6 M 
insulin. Left, protein levels of GRB2; center, protein 
levels of Nck; and right, protein levels of Syp are graphed 
as % control (LG-I) ± SEM, n=22. * indicates a significant 
difference (p<0.05) as compared to control. 
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Rat Streptozotocin-Induced IDDM 
The expression of all six signaling components was 
studied in this in vivo model of IDDM to determine if high 
glucose levels in the absence of high insulin are associated 
with any alterations in the levels of these proteins. 
Insulin receptor. The protein levels of the insulin 
receptor were altered somewhat differently in fat and liver 
of streptozotocin-treated rats as compared to control rats. 
In liver, the expression of the insulin receptor was 
significantly elevated to 183±25% of control (fig. 21, 
left). In epididymal fat, the average receptor protein 
level was 130.6±11.4% of control, although this difference 
was not significant (fig. 22, left). In both tissues, the 
mRNA levels were significantly elevated in the 
streptozotocin-treated rats compared to the control rats. 
The elevation in liver tissue was associated with an 
increase in the 9.5 kb transcript (fig. 21, center). The 
higher mRNA levels in epididymal fat were mainly associated 
with an increase in 7.5 kb transcripts, although the 9.5 kb 
receptor mRNA was also significantly higher than in the 
control animals (figure 22, center). 
In addition to the differences in receptor protein 
expression between the two groups in both tissues, the ratio 
of the 9.5 to 7.5 kb transcripts was tissue-specific as 
well. In liver tissue, control rats had a significantly 
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Fig. 21. Graphed results of the protein and RNA levels of 
the insulin receptor in rat liver. C=control rats; STZ=rats 
made insulin-deficient by streptozotocin treatment. Left, 
protein levels are represented as % control ± SEM, n=9. 
Center, the RNA levels are graphed as %control ± SEM for 
both the 9.5 and 7.5 kb species, n=7 control and 9 STZ. The 
solid bar represents the amount of 9.5 kb transcript, while 
the hatched bar represents the amount of 7.5 kb trnscript. 
Right, the relative ratios of the 9.5 and 7.5 kb transcripts 
are shown as % of the total insulin receptor transcripts 
(9.5+7.5 kb) for both treatment groups. * indicates a 
significant difference {p<0.05) as compared to control or 
between the bracketed groups. 
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higher ratio of 7.5 kb transcripts, and streptozotocin 
treatment reversed this ratio {fig. 21, right). In 
epididymal fat, the control animals had a significantly 
higher ratio of 9.5 kb transcripts, while the 
streptozotocin-treated animals had roughly an equal amount 
of each transcript {fig. 22, right). 
IRS-1. The mRNA levels for IRS-1 were also increased 
in both fat {fig. 23, right) and liver tissue {fig. 24) of 
streptozotocin-diabetic rats as compared to control rats. 
This increase was to 198.6±28.5% control and 217±18.4% 
control in fat and liver, respectively. Unlike the 
expression of the insulin receptor, the elevated IRS-1 mRNA 
levels were not associated with a concomitant increase in 
the IRS-1 protein in fat tissue. In fact, IRS-1 protein 
levels in epididymal fat of streptozotocin-treated rats was 
significantly lowered to 62.2±4.7% of control {fig. 23, 
left). The protein levels for IRS-1 in rat liver were not 
measurable on western blots due to a nonspecific band which 
was recognized by several anti-IRS-1 antibodies. This 
protein was very highly expressed in comparison to IRS-1, 
and the proximity of this protein to IRS-1 on SOS-PAGE gels 
was so close that its signal overshadowed IRS-1 expression. 
Substantial evidence suggests that this band represents a 
nonspecific protein interaction. First, the band migrated 
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Fig. 22. Graphed results of the protein and RNA levels of 
the insulin receptor in rat epididymal fat. C=control rats; 
STZ=rats made insulin-deficient by streptozotocin treatment. 
Left, protein levels are represented as % control ± SEM, 
n=9. Center, the RNA levels are graphed as %control ± SEM 
for both the 9.5 and 7.5 kb species, n=9 control and 7 STZ. 
The solid bar represents the amount of 9.5 kb transcript, 
while the hatched bar represents the amount of 7.5 kb 
trnscript. Right, the relative ratios of the 9.5 and 7.5 kb 
transcripts are shown as % of the total insulin receptor 
transcripts (9.5+7.5 kb) for both treatment groups. ** and 
*** indicate a significant difference (p<0.01 and p<0.001, 
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Fig. 23. Graphed results of the protein and RNA levels of 
IRS-1 in rat epididymal fat. C=control rats; 
STZ=streptozotocin-treated rats. Left, protein levels are 
represented as % control ± SEM, n=9. Right, the RNA levels 
are graphed as %control ± SEM, n=9 control and 7 STZ. ** 






















Fig. 24. Graphed results of the RNA levels of IRS-1 in rat 
liver. C=control rats; STZ=streptozotocin-treated rats. 
The RNA levels are graphed as %control ± SEM, n=18 control 
and 17 STZ. *** indicates a significant difference 
(p<0.001) as compared to control. 
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slightly ahead of the positive control, which normally lined 
up with IRS-1. Secondly, IRS-1 is expressed at very low 
levels in all tissues studied, and the expression of this 
band was much too high to have been IRS-1. Third, there was 
a faint band that lined up with the positive control which 
was not quantitatable due to the high expression of the 
nonspecific band (data not shown). 
PI3K p85a. In epididymal fat, streptozotocin treatment 
had no effect on the expression of p85a at the protein or 
mRNA levels (fig. 25). In contrast, liver tissue of 
streptozotocin-treated rats showed a 68.9±12.7% increase in 
the expression of p85a protein over the expression in liver 
tissue from control rats (fig. 26, left). This increase in 
p85a protein was not clearly reflected at the RNA level, as 
there was only a slight nonsignif icant increase in p85a mRNA 
between control and streptozotocin-treated animals in liver 
tissue (fig. 26, right). 
GRB2. Nck, and Syp. Like the receptor, IRS-1, and 
p85a, the expression of GRB2, Nck, and Syp tended to be 
regulated in the opposite manner in this model of IDDM 
(streptozotocin-treated rats) from the NIDDM model (KKAY 
mice), as shown in figs. 27 and 28. In epididymal fat and 
liver tissue, there was no difference in the expression of 
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Fig. 25. Graphed results of the protein and RNA levels of 
PI3K p85a in rat epididymal fat. C=control rats; 
STZ=streptozotocin-treated rats. Left, protein levels are 
represented as % control ± SEM, n=9 control and 8 STZ. 
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Fig. 26. Graphed results of the protein and RNA levels of 
PI3K p85a in rat liver. C=control rats; STZ=streptozotocin-
treated rats. Left, protein levels are represented as % 
control ± SEM, n=9. Right, the RNA levels are graphed as 
%control ± SEM, n=7. *** indicates a significant difference 
(p<0.001) between the two groups. 
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GRB2, Nck, and Syp Protein in Rat IDDM 
(Epididymal Fat) 
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Fig. 27. The expression of GRB2, Nck, and Syp protein in 
rat epididymal fat. C=control rats; STZ=streptozotocin-
treated rats. Left, protein levels of GRB2; center, protein 
levels of Nck; and right, protein levels of Syp are graphed 
as % control ± SEM, n=9 control and 8 STZ. * indicates a 
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Fig. 28. The expression of GRB2, Nck, and Syp protein in 
rat liver. C=control rats; STZ=streptozotocin-treated rats. 
Left, protein levels of GRB2; center, protein levels of Nck; 
and right, protein levels of Syp are graphed as % control ± 
SEM, n=9. * and *** indicate a significant difference of 
p<0.05 or p<0.001 as compared to control, respectively. 
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27 and 28, left). Nck protein levels were significantly 
reduced to 70.87±6.5% of control in liver tissue of 
streptozotocin-treated animals, while Nck expression was 
unchanged in epididymal fat (figs. 27 and 28, center). Syp 
protein levels were significantly decreased to 71.8±9.3 and 
61.2±4.4% of control in fat and liver tissues, respectively 
(figs. 27 and 28, right). 
CHAPTER V 
DISCUSSION 
Because NIDDM is associated with a variety of metabolic 
derangements (2-5,120), and the cause of insulin resistance 
probably lies in a post-receptor defect in most cases, this 
project focused on studying early insulin signaling events 
as possible sites of defects. Earlier signal transduction 
defects would likely lead to multiple downstream 
derangements, particularly if alterations occurred before 
insulin's signal branched to elicit its many different 
cellular effects. 
The current study indicates that there are multiple 
alterations in the expression and function of components 
involved in the first stages of insulin signal transduction 
in diabetic KKAY mouse tissues as compared to control 
nondiabetic animals. The expression and function of the 
insulin receptor, IRS-1, and PI3K p85a were found to be 
defective to varying degrees in KKAY mice. Conversely, 
GRB2, Nck, and syp levels were elevated in KKAY mice as 
compared to nondiabetic controls. 
However, results from the in vitro model of insulin 
resistance suggest that many of these alterations are likely 
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a result of hyperinsulinemia and hyperglycemia associated 
with the diabetic condition. Also, hyperglycemia with 
hypoinsulinemia tended to regulate the expression of these 
signaling components in the opposite direction from 
hyperglycemia with hyperinsulinemia relative to control 
animals. Therefore, the pathophysiology associated with the 
insulin-resistant diabetic condition of KKAY mice, 
particularly hyperinsulinemia, may be responsible for the 
observed alterations. PI3K p85a expression was the 
exception, as it was decreased in adipose from KKAY mice 
relative to control, but not significantly altered in 3T3-Ll 
cells pre-fed with high levels of glucose and insulin. 
Pioglitazone treatment of KKAY mice had little effect 
on the expression or function of any of the proteins 
studied. While pioglitazone treatment increased PI3K p85a 
levels in KKAY fat to control levels, this increase in 
expression did not result in an increase in p85a associated 
with IRS-1 on insulin stimulation of adipocytes from 
pioglitazone-treated KKAY mice compared to untreated KKAY 
mice. Therefore, pioglitazone probably elicits its insulin-
sensitizing effect in this model of insulin-resistant 
diabetes by a mechanism other than the alteration of the 
expression or function of early signaling components. 
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Proteins with Altered Expression or Function in KKAY Mice or 
Streptozotocin-treated Rats 
The Insulin Receptor 
Expression 
The protein levels of the insulin receptor in fat and 
liver from insulin-resistant KKAY mice were lower than 
receptor levels in either tissue from nondiabetic C57 
controls (fig. 2). However, high amounts of insulin have 
been shown to cause internalization and degradation of the 
insulin receptor (169,170), and the enzyme responsible for 
at least part of the degradation of the insulin receptor is 
a lysosomal thiol protease (170). In the 3T3-Ll cells pre-
fed with high insulin and high glucose, a similar decrease 
in the amount of insulin receptor protein was seen (fig. 
14), suggesting that the lower levels of receptor protein in 
the KKAY mice may be due to the high circulating insulin 
levels in these animals. 
Further evidence supporting this concept lies in the 
regulation of the RNA levels for the insulin receptor. In 
KKAY mice, the RNA levels for the insulin receptor are not 
significantly lower than in C57 mice with the exception of 
the 7.5 kb transcript in liver (fig. 4). A significant 
difference in receptor RNA levels existed in the 3T3-Ll 
cells pre-fed with high glucose and high insulin as compared 
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to control cells, although this difference was only about 
25% {fig. 14). This is about the same magnitude as the 
difference between the mean receptor RNA levels between KKAY 
and C57 mice. The fact that this difference is significant 
in the cell culture experiment, but not the animal 
experiment, may be a result of the smaller variation in cell 
culture as opposed to animal studies. The differences in 
mRNA {about 25% control) are much smaller than the 
differences in protein in either study, suggesting a 
regulation of the receptor at the protein level, most likely 
due to insulin receptor internalization and degradation. 
Comparable results were found by Ludwig, et al. in livers of 
genetically obese and hyperinsulinemic mice, where receptor 
number was decreased even though mRNA levels were increased 
compared to controls {171). 
Interestingly, insulin receptor mRNA levels were 
upregulated in fat and liver of the insulin-deficient 
streptozotocin-diabetic rats compared to control tissues, 
and liver tissue demonstrated a significant concordant rise 
in receptor protein (fig. 21 and fig. 22). Similar results 
were found by Tozzo, et al., where both the 7.5 and 9.5 kb 
transcripts were increased 10-fold in liver tissue of 
streptozotocin-treated rats (172). This increase was due to 
an increase in transcription of the insulin receptor gene, 
and also resulted in increased insulin binding to liver 
plasma membranes by 40% (172). In this case, the RNA and 
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protein were upregulated in the absence of insulin. Such 
changes may represent cellular compensations to upregulate 
receptors when there is insufficient insulin to elicit 
normal effects. 
If this were the case, there should have been a similar 
rise in insulin receptor mRNA in the insulin-resistant 3T3-
Ll cells or tissues from KKAY mice, as opposed to the 
observed decrease in both models (fig. 4 and fig. 14). 
Therefore, high insulin levels probably lower insulin 
receptor mRNA levels as well as receptor protein levels in 
KKAY mice. To support the data shown in figs. 2, 4, 14, 21, 
and 22, the expression of the insulin receptor was regulated 
in a manner similar to KKAY mice in liver and muscle of 
insulin-resistant ob/ob mice (173), while receptor levels 
were increased in tissues of streptozotocin-treated rats 
( 173) . 
The physiological significance of insulin receptor 
regulation can be partially explained using the concept of 
spare receptors. Normal cells possess many more insulin 
receptors than are necessary to produce maximal cellular 
responses in the presence of physiological concentrations of 
insulin (174). Insulin-stimulated glucose oxidation is 
maximal in isolated fat cells when only 8-10% of the 
receptors are occupied {174). There are two major 
advantages to the presence of spare receptors in insulin-
sensi ti ve tissues. First, spare receptors protect cells 
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from hypoglycemia following the surge of insulin in response 
to a glucose challenge because the maximal effects are 
attained at an insulin concentration well below the 
concentration needed to bind all of the receptors. 
Secondly, spare receptors help to prevent hyperglycemia when 
there is a sudden loss of receptors (174). However, spare 
receptors are not actually "spare," since decreasing 
receptor number causes a subsequent loss in sensitivity, 
requiring more insulin to elicit the maximal cellular 
effects (174). Therefore, the lower amount of insulin 
receptors in KKAY mice probably contributes to the diabetic 
condition by making the cells less responsive to insulin, 
even though the receptor number was above the 8-10% of 
control involved in binding insulin in normal cells. 
Pioglitazone treatment significantly increased receptor 
protein levels toward control levels in KKAY epididymal fat 
(p<0.05 between KKAY and KKAY + pioglitazone treatment), 
although there was not a statistically significant effect of 
pioglitazone on receptor levels in liver tissue (fig. 2). 
There was also no significant effect of pioglitazone on 
receptor mRNA levels. This seems to indicate that the 
effect of pioglitazone treatment on receptor expression, if 
any, is secondary to some other effect of pioglitazone. The 
effect of pioglitazone treatment on receptor number in fat 
is likely a result of the lowering of serum insulin levels 
and a subsequent partial alleviation of the insulin 
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dowhregulation of the receptor (20). This effect does not 
seem to change receptor binding, however, since pioglitazone 
was not found to significantly alter insulin binding 
(17,20,44). Therefore, while increased receptor number 
should increase insulin binding (174), the small increase in 
receptor number resulting from pioglitazone treatment of 
KKAY mice may not be large enough to create a significant or 
detectable change in insulin binding. 
Alternate Splicing of the Insulin Receptor 
Although several transcript sizes of the insulin 
receptor have been reported (59), there are four main 
splicing products that result from alternate splicing of 
exon 11 in the a subunit (57,58,75-81,175,176) and alternate 
poly-A site selection (59). Agarose gel electrophoresis of 
total RNA can only distinguish between the 9.5 kb and 7.5 kb 
species, which differ by alternate poly-A-site selection 
(59). The poly-A site selection occurs independently of the 
splicing of exon 11, resulting in four possible products. 
The ratio of 9.5 to 7.5 kb transcripts did not differ 
between KKAY and control mice (data not shown), nor did the 
ratio of exon 11+ to exon 11- between these groups (Susan 
Sell, phone conversation, March 1994) in muscle, fat, or 
liver tissue. In the 3T3-Ll adipocytes pre-treated with 
high glucose and high insulin, the ratio of 9.5 to 7.5 kb 
transcripts changed from a significantly higher percent of 
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9.5 than 7.5 kb transcripts in the control cells (55.66±1.3% 
9.5 kb, 44.3±1.3% 7.5 kb; p<0.001, n=16) to an even ratio 
(50.5±1.3% 9.5, 49.5±1.3% 7.5; p>0.05, n=16), as is shown in 
fig. 14. Therefore, insulin and glucose may regulate the 
poly-A site selection of this transcript, though there is no 
known functional difference between the 9.5 and 7.5 kb 
transcripts (59). 
In contrast to the insulin-resistant animals, the 
streptozotocin-treated rats showed opposite trends for 
insulin receptor transcript poly-A site selection compared 
to transcripts from control animal tissues (fig. 21 and fig. 
22). There was also a tissue-specific difference in the 
ratio of these transcripts, even in the control animals. 
While control liver had a higher percentage of 7.5 kb 
transcripts, fat tissue possessed a higher percentage of 9.5 
kb transcripts. Streptozotocin-treatment reversed this 
ratio in liver (fig. 21) and equalized it in fat (fig. 22), 
indicating that the streptozotocin-induced diabetic 
condition may alter RNA processing. It is interesting to 
note that treatment of 3T3-Ll adipocytes with high glucose 
and high insulin had the same effect on the ratio of these 
transcripts as did streptozotocin-induced diabetes on such 
transcripts in fat tissue. Due to the similarity of the 
tissue and cells (fat and adipocytes), it may be that poly-A 
site selection is altered by the elevated glucose present in 
both experimental models. However, the same effect was not 
seen in hyperglycemic KKAY mice as compared with C57 mice 
(data not shown), although there are many more factors 
influencing the tissues in this polygenic model (36,37). 
Kinase Activity 
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Insulin-stimulated adipocytes isolated from C57 animals 
showed an 11-fold increase in the tyrosine-phosphorylation 
of the insulin receptor~ subunit (fig. 7 and fig. 8), while 
control 3T3-Ll cells showed a 25-fold increase when acutely 
stimulated with insulin. This response was obliterated in 
insulin-resistant, hyperglycemic KKAY mice as well as in 
3T3-Ll cells pre-fed with high insulin and high glucose, 
suggesting that the high insulin and high glucose levels may 
contribute to the insulin resistance of these cells (fig. 7, 
fig. 8, and fig. 15). In both the animal and cell culture 
models of insulin resistance, the basal tyrosine 
phosphorylation of the receptor ~ subunit was increased well 
above the basal tyrosine phosphorylation of the receptor in 
control cells (fig. 8 and fig. 15), probably due to the high 
levels of circulating insulin. Another possibility is that 
the high glucose concentrations in both models could be 
inhibiting the insulin receptor kinase, since it has been 
shown that incubation of rat-1 fibroblasts with high glucose 
concentrations led to inhibition of the receptor kinase 
(42,43). The insulin dose-response curves in 3T3-Ll cells 
reflected an inhibition of insulin-stimulated glucose uptake 
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in the cells pre-fed with high glucose only (fig. 13), but 
it was also evident that treatment with high levels of 
insulin alone caused an even greater inhibition (fig. 13). 
It is possible that hyperphosphorylation of the insulin 
receptor could lead to inhibition of its kinase activity. 
There is evidence that the c-terminal tyrosines 1316 and 
1322 may play a role in negatively regulating the insulin 
receptor kinase (63,64). Mutation of these tyrosines to 
phenylalanine caused an increase in the phosphorylation of 
the receptor and IRS-1, along with an increase in p85 
association with IRS-1, an increase in PI3K activity, and an 
increase in MAP kinase activity (64). Therefore, when these 
residues are phosphorylated, they may play a role in turning 
off receptor signaling in normal cells when the insulin 
levels are high enough to elicit the desired effects, or 
these residues could possibly inhibit the receptor in the 
hyperinsulinemic condition. 
However, because of the nature of the methodology used 
to measure phosphotyrosine in this study, it is possible 
that acutely-stimulated receptor phosphorylation could not 
be measured due to the high amount of basal phosphorylation 
of the ~ subunit in the insulin-resistant condition. While 
there are many potential tyrosine phosphorylation sites per 
receptor, it is not known whether the binding of one or more 
antibody molecules to phosphotyrosines on the receptor could 
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block further antibody binding to additional phosphorylated 
tyrosines after insulin stimulation. 
Another factor to be considered is that although the 
insulin resistant cells of both models have a higher degree 
of basal receptor tyrosine phosphorylation, they also have 
fewer receptors. To aid in interpreting this data, the 
phosphorylation per unit receptor was graphed in fig. 9 and 
fig. 15. Presentation of the data in this way accentuated 
the increased basal phosphorylation of the ~ subunit in the 
KKAY mice and 3T3-Ll cells treated with high glucose and 
high insulin. 
Similar results were found by Kanety, et al. in the 
sand rat model of insulin-resistant diabetes (177). In this 
model, the animals were induced to a state of 
hyperinsulinemia in the absence of hyperglycemia by altering 
their diet. This state of insulin resistance was associated 
with a decrease in the number of insulin receptors and an 
inhibition of the receptor kinase, while the basal receptor 
phosphorylation was increased (177). Upon restriction of 
the diet, these receptor defects were brought back to 
control levels. Comparable results were also found in 
adipocytes from NIDDM patients, where there was an observed 
decrease in the insulin-stimulated tyrosine phosphorylation 
of insulin receptors (53). Such patients did not have a 
decreased number of insulin receptors (53), presumably due 
to the tighter metabolic control maintained in human-studies 
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compared to the extreme hyperglycemia and hyperinsulinemia 
in experimental KKAY mice. 
In the present study, pioglitazone had no effect on the 
insulin-stimulated insulin receptor kinase 
autophosphorylation in KKAY mice (fig. 8 and fig. 9). This 
differs slightly from reports by Kellerer, et al. and 
Maegawa, et al. in which troglitazone or pioglitazone 
treatment reversed the inhibition of the insulin receptor 
kinase in rat-1 fibroblasts pre-fed with high glucose 
(42,43). Pioglitazone was also shown to correct receptor 
phosphorylation defects in Wistar fatty rats (16) and high-
fat-fed rats (44). In another study, however, pioglitazone 
increased insulin stimulation of PI3K activity without 
increasing receptor phosphorylation in 3T3-Ll cells 
overexpressing insulin receptors and in L6 myotubes (48). 
The difference between these studies and ours could 
represent a difference in the systems studied, or possibly a 
difference in methodology. In the present study, whole cell 
lysates were examined, so that the receptor number and 
phosphorylation is indicative of the total amount of 
receptor ~ subunits. The other studies purified the insulin 
receptors using wheat germ agglutinin (WGA). WGA binds 
carbohydrate moieties present on both a and ~ subunits, 
although the a subunits are glycosylated to a greater extent 
than the~ subunits (74). Such methods would purify and 
evaluate mostly whole receptors. My study examined only the 
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receptor ~ subunit population, which may include 
phosphorylated ~ subunits separated from a subunits during 
degradation of the receptor. This possibility exists 
because phosphotyrosines in the juxtamembrane domain 
(67,169,178,179), kinase domain (169,178,180), and c-
terminus (66,169) have all been shown to be involved in 
receptor internalization. Such measures may reflect 
elevated baseline phosphorylation of the ~ subunit, thus 
diminishing the observed proportion of insulin-stimulated 
phosphorylation of the receptor. 
IRS-1 
Expression 
The protein levels of IRS-1 were not significantly 
different between control and KKAY mice in fat or liver 
(fig. 2), even though the IRS-1 mRNA levels were 
significantly lower in KKAY mice as compared to control in 
both tissues (fig. 5). These findings differ slightly from 
previous findings by Saad, et al. in another animal model of 
NIDDM, ob/ob mice. The protein levels for IRS-1 in ob/ob 
mice were found to be significantly lower in liver tissue as 
compared to nondiabetic ob/+ controls, while IRS-1 
expression was unaltered in muscle tissue (173). 
Unfortunately, fat tissue was not a part of that study. 
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Saad, et al. also investigated the expression of IRS-1 
protein in the streptozotocin-treated rat model of IDDM. 
IRS-1 protein expression was unaltered in either liver or 
muscle tissue from streptozotocin-treated rats as compared 
to control (173). In our study, IRS-1 mRNA abundance was 
increased in fat and liver tissues of streptozotocin-treated 
diabetic animals as compared to nondiabetic controls (fig. 
23 and fig. 24, respectively). However, IRS-1 protein was 
not concomitantly increased but was in fact somewhat 
decreased in fat of these streptozotocin-treated animals 
(fig. 23). 
IRS-1 protein was not detectable in rat liver tissue 
due to the presence of a nonspecific band of approximately 
the same size as IRS-1. This nonspecific protein was very 
highly expressed in comparison to IRS-1, and the proximity 
of this protein to IRS-1 on SOS-PAGE gels was so close that 
its signal masked IRS-1 expression. Substantial evidence 
suggests that this band represents a nonspecific protein 
interaction. First, the band migrated slightly ahead of the 
positive control, which normally lined up with IRS-1. 
Secondly, IRS-1 is expressed at very low levels in all 
tissues studied, and the expression of this band was much 
too high to have been IRS-1. Third, there was a faint band 
that lined up with the positive control which was not 
quantitatable due to the high expression of the nonspecific 
band (data not shown). Therefore, it is difficult to 
determine whether our data is in full agreement with the 
work of Saad, et al. (173), since fat was not a part of 
their study, nor did they measure RNA levels in either 
model. 
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IRS-1 expression has also been shown to be affected by 
insulin levels at the level of protein stability (181-183). 
IRS-1 is degraded in 3T3-Ll adipocytes pre-treated with high 
insulin concentrations (1 µM) by an extra-lysosomal calcium-
dependent protease into two fragments of 79 and 90 kDa 
(181,182). Based on these studies, it would seem logical 
that the hyperinsulinemia of KKAY mice would have an effect 
on protein levels of IRS-1. In contrast, there were no 
observed differences between KKAY and C57 IRS-1 levels in 
fat or liver (fig. 2). One possible explanation for the 
lack of an observed decrease in IRS-1 protein levels in 
hyperinsulinemic KKAY mice is that the insulin levels of 
these animals (500 µU/ml) only corresponds to an insulin 
concentration of 3 nM, which may not be high enough to 
elicit insulin-induced proteolysis of IRS-1. One 
dissimilarity between the present study and the prior 
studies (181,182) is that we failed to achieve statistically 
significant effects of insulin to lower IRS-1 protein levels 
in 3T3-Ll cells pre-fed overnight with 2 µM insulin (fig. 
17), although the mean values for IRS-1 protein in the 
insulin-treated cells tended to be lower than control cells. 
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Phosphorylation 
As is shown in fig. 7 and fig. 10, the basal 
phosphorylation of IRS-1 is not elevated in KJ<AY mice as 
compared to control C57 mice. This is different from the 
high basal phosphorylation of the insulin receptor in these 
animals (fig. 7 and fig. 8). However, like the insulin 
receptor, acute insulin treatment did not stimulate tyrosine 
phosphorylation of IRS-1 in adipocytes from KKAY mice or KKAY 
mice treated with pioglitazone. This was not surprising, 
since specific increases in insulin receptor tyrosine 
autophosphorylation are required for subsequent IRS-1 
phosphorylation (67,94,184-186). 
The hyperglycemic and hyperinsulinemic condition 
probably plays a role in the lack of IRS-1 phosphorylation 
in insulin-stimulated KKAY adipocytes, since the 3T3-Ll 
cells pre-fed with high insulin and high glucose were 
likewise unresponsive (fig. 18). Another study likewise 
showed a decrease in the responsiveness of 3T3-Ll cells to 
insulin-stimulated phosphorylation of IRS-1 after a 24 hr 
incubation of the cells in 100 nM insulin (183). Insulin 
pre-treatment of the 3T3-Ll cells in both cases also led to 
an increase in the basal tyrosine phosphorylation of IRS-1 
(fig. 18). 
Pioglitazone treatment of KKAY mice did not restore the 
insulin-stimulated tyrosine phosphorylation of IRS-1 (fig. 7 
and fig. 10). As mentioned above, pioglitazone and 
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troglitazone have both been shown to increase receptor 
tyrosine kinase activity for autophosphorylation and 
phosphorylation of synthetic substrates (16,42-44), although 
there is one study by Zhang, et al. in which no effect of 
pioglitazone treatment was seen on insulin-stimulated 
phosphorylation of the insulin receptor or IRS-1 (48). The 
study by Zhang, et al. and another by Sizer, et al. (47), 
although done in nonphysiologic cell culture models, both 
suggested a more direct effect of pioglitazone on PI3K 
activity. Therefore, it is possible that the increased 
insulin sensitivity (20) and insulin-stimulated glucose 
transport (18) in KKAY mice treated with pioglitazone may be 
due to a more direct effect of pioglitazone further 
downstream in the insulin-signaling pathway than IRS-1. 
Siqnif icance of IRS-1 Function 
It should be noted that expression of a nonfunctional 
IRS-1 molecule in transgenic IRS-1 knockout mice resulted in 
a decrease in both pre-and post-natal growth as well as 
insulin resistance (109,110). However, the viability of 
these animals homozygous for disrupted IRS-1 suggests that 
there are IRS-1-independent pathways in insulin signaling to 
both mitogenic and metabolic effects. In fact, in one of 
these studies, Araki, et al. found that another IRS-like 
molecule immunologically distinct from IRS-1 and slightly 
larger was discovered to be tyrosine-phosphorylated by 
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insulin stimulation {110). It is therefore likely that 
alterations observed in IRS-1 expression or phosphorylation, 
while they may contribute to insulin resistance or lack of 
insulin signaling to growth effects, may not be entirely 
disruptive to cellular processes due to the existence of 
alternate pathways of signaling from the insulin receptor 
( 110) • 
On the other hand, IRS-1 is a multisite docking 
protein, binding to at least four different proteins on 
insulin stimulation of the insulin receptor and consequent 
tyrosine phosphorylation of IRS-1 {10,91,116-120). These 
four proteins, PI3K p85a, GRB2, Nck, and Syp, are thought to 
branch insulin's signal to various cellular processes 
{10,91). Therefore, IRS-1 is probably a very important 
molecule in insulin signaling even though there are likely 
other substrates of the receptor as well. One such 
substrate, She, may actually be more important than IRS-1 in 
insulin signaling through GRB2 {105,116,141-143,145) and 
will be discussed in more detail below. 
PI3K p85a 
Expression 
The expression of PI3K p85a was measured using a 
monoclonal antibody directed against the SH2 domains of 
p85a. As seen in fig. 2, two major bands of approximately 
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the same size are recognized by this antibody in fat tissue. 
This may be due to cross-reactivity with another protein, 
p87P, which has high homology to p85a (128). While both 
proteins may associate with the pllO subunit (128), we have 
found that only the lower band (p85a) associates with IRS-1 
on insulin stimulation of isolated adipocytes (fig. 11). In 
addition, the lower band was aligned with the baculovirus-
expressed p85a positive control, while the upper band did 
not. Also, a recently available antibody specific for the 
SH3 domains of p85a detected only the lower of the two bands 
in fat tissue (data not shown). For these reasons, the 
lower band observed in fat tissue was quantitated as p85a. 
PI3K p85a protein levels in liver of diabetic KKAY mice 
were not significantly different from the levels in liver 
tissue of nondiabetic control animals (fig. 2), and there 
was no effect of pioglitazone treatment. In contrast, p85a 
protein levels were significantly decreased in epididymal 
fat tissue of KKAY mice by 53% relative to the C57 p85a 
levels (fig. 2). The correction of p85a levels in KKAY fat 
by pioglitazone treatment occurred in the absence of a 
concordant increase in p85a mRNA, indicating that 
pioglitazone treatment may increase p85a levels in adipose 
by augmenting p85a translation or protein stability. Such 
findings support two conclusions. First, the expression of 
p85a in KKAY mice is regulated differently in fat than in 
liver tissue. Secondly, the action of pioglitazone on p85a 
expression appeared to be tissue-specific and post-
transcriptional. 
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The decreased expression of p85a in KKAY fat does not 
seem to be caused by the diabetic condition. First, if the 
decreased expression was due to the high circulating insulin 
and glucose levels of the KKAY mice, one would expect to see 
the same decreased expression in liver tissue as in the case 
of the insulin receptor; however, this difference could be 
explained by tissue-specific regulation. Secondly, the 
results from the 3T3-Ll cells indicated that high insulin 
and glucose actually caused a near-significant increase 
(p=0.052) in PI3K protein levels over the expression in 
control cells (fig. 19). Likewise, another group found a 
slight increase in PI3K protein levels with a 24 hr 
pretreatment of 3T3-Ll cells with high insulin alone (181). 
Hyperglycemia in the absence of hyperinsulinemia showed 
a tissue-specific effect in the opposite direction from that 
observed in KKAY mice. In epididymal fat from 
streptozotocin-treated insulin-deficient rats, there was no 
significant difference in p85a protein or RNA levels 
relative to control (fig. 25). In liver tissue, PI3K p85a 
protein levels were 68.9 ± 12.7% higher than control (n=9, 
p=0.0006). Once again, there was not a similar increase in 
p85a mRNA (fig. 26). Although the tissue-specific increase 
cannot be explained, one possibility is that p85a is 
regulated in a tissue-specific manner by the hyperglycemic 
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hypoinsulinemic condition itself. This is quite plausible 
owing to the differing glucose uptake properties of fat 
verses liver. Liver is more freely permeable to glucose due 
to the higher Km of the GLUT2 glucose transporter compared 
to fat tissue, which expresses the low Km GLUT4 (187). As a 
result, liver may be more susceptible to the effects of 
hyperglycemia than fat. 
Insulin-Stimulated Association with IRS-1 
There is considerable evidence to suggest that PI3K 
p85a associates with IRS-1 on insulin stimulation 
(10,91,100-102,106,lll-113,115,119,l26,134-139). As shown 
in fig. 11, p85a was found in anti-IRS-1 immunoprecipitates 
in the insulin-stimulated adipocytes from nondiabetic 
control animals, but very little was found in the non-
stimulated control cells. However, the association of p85a 
with IRS-1 was not stimulated by insulin in adipocytes 
isolated from KKAY mice or KKAY mice treated with 
pioglitazone (fig. 11, fig 12). This finding is consistent 
with the lack of insulin-stimulated tyrosine phosphorylation 
of the insulin receptor and IRS-1 in adipocytes from these 
groups (figs. 7, 8, and 10), since IRS-1 must be tyrosine-
phosphorylated to associate with the SH2 domains of PI3K 
p85a (100,101,112,113). 
The failure of KKAY adipocytes to show insulin-
stimulated phosphorylation of IRS-1 and recruitment of p85a 
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to IRS-1 complexes has implications regarding sensitivity of 
these cells to insulin. The association of p85a to 
phosphorylated IRS-1 activates the catalytic activity of the 
pllO subunit of PI3K, an action related to insulin 
stimulation of GLUT4 glucose transporter recruitment to the 
plasma membrane and insulin-stimulated glucose uptake 
(95,96,98,99,102,111). In epididymal fat from KKAY mice, 
the expression of GLUT4 was reported to be decreased 
relative to control C57 mice (18). In the present study, 
the expression of p85a, the insulin-stimulated 
phosphorylation of the receptor and IRS-1, and the 
association of p85a with IRS-1 were all found to be lower 
than normal. These combined alterations in adipose tissue 
likely contribute to the insulin resistance of these 
animals, since glucose uptake through GLUT4 is the primary 
mechanism by which insulin stimulates glucose transport into 
these cells (188). Other studies would suggest that a 
defect in recruitment of GLUT4 to the plasma membrane is 
more likely than a defect in expression of GLUT4 in NIDDM 
(187), although the present data and past results from this 
laboratory (18) suggest that both defects may exist in KKAY 
mice. 
One point that becomes apparent from the data in figs. 
11 and 12 is that pioglitazone treatment did not increase 
the amount of p85a in anti-IRS-1 immunoprecipitates of 
insulin-stimulated isolated adipocytes, even though 
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pioglitazone treatment corrected the levels of p85a in the 
treated animals (fig. 2). This result may indicate that the 
correction of p85a levels by pioglitazone treatment as shown 
in fig. 2 is unrelated to the correction of blood glucose 
levels by pioglitazone. However, Dailey, et al. found that 
insulin-stimulated isolated abdominal adipocytes from 
pioglitazone-treated KKAY mice showed an increased amount of 
PI3K activity in anti-phosphotyrosine immunoprecipitates as 
compared to non-treated KKAY adipocytes (189). 
While these results seem contradictory to my findings, 
there are several possible explanations for this difference. 
First, Dailey et al. used anti-phosphotyrosine 
immunoprecipitates, which are not necessarily the same as 
anti-IRS-1 immunoprecipitates. While IRS-1 needs to be 
phosphorylated for the association with p85a to occur, the 
anti-phosphotyrosine antibodies immunoprecipitate a plethora 
of tyrosine-phosphorylated proteins. It is possible, then, 
that an anti-phosphotyrosine immunoprecipitation could 
precipitate unidentified phosphotyrosine-containing proteins 
other than IRS-1, which may also associate with p85a. The 
presence of an IRS-2 in IRS-1 knockout mice is an example of 
a possible alternate substrate for the receptor (110). 
There are several reports of p85a association with the 
insulin receptor alone (190-192), although this is 
controversial (115). Also, there are reports documenting 
insulin-stimulated tyrosine phosphorylation of p85a 
{125,133). 
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Another difference is that Dailey et al. measured PI3K 
activity, while fig. 11 demonstrates the amount of p85a 
protein in the IRS-1 immunoprecipitates. This difference 
may mean that the activity measurement is more sensitive 
than the measurement of the amount of protein in 
immunoprecipitates, or possibly that pioglitazone acted to 
increase the activity of the enzyme in the absence of an 
association with IRS-1. 
Finally, the PI3K activity data generated by Dailey, et 
al. were obtained from abdominal rather than epididymal fat 
{189). The same study showed a higher responsiveness of 
abdominal fat to insulin and pioglitazone as compared to 
epididymal fat (189). Therefore, the effect of pioglitazone 
on insulin-stimulated PI3K association with IRS-1 may not be 
detectable in epididymal fat to the same extent as 
pioglitazone's effect on PI3K activity in abdominal fat. 
One other study by Zhang, et al. showed results 
corresponding to the data shown in fig. 6, as well as the 
results of Dailey, et al. Pioglitazone-treated Chinese 
hamster ovary cells overexpressing the insulin receptor 
showed an increase in the insulin-stimulated PI3K activity 
in anti-phosphotyrosine immunoprecipitates as compared to 
such activity in untreated cells. At the same time, there 
was not an increase in the tyrosine phosphorylation of the 
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insulin receptor or IRS-1 (48). There was also an increase 
in the amount of PI3K p85a protein in anti-phosphotyrosine 
immunoprecipitates in the pioglitazone-treated cells over 
the control cells (48). Therefore, although the present 
studies failed to detect an effect of pioglitazone treatment 
on PI3K association with IRS-1 (fig. 11 and fig. 12), 
pioglitazone may actually be acting at this level to 
increase insulin sensitivity and insulin-stimulated glucose 
uptake through GLUT4. 
There is one additional report suggesting another 
possible mechanism of pioglitazone action. sizer, et al. 
showed that pioglitazone treatment of 3T3-Ll cells prevented 
isoproterenol-induced inhibition of insulin-stimulated PI3K 
activity (47). such results indicated that pioglitazone 
inhibited a cAMP-dependent negative control mechanism, since 
the drug also prevented the inhibition of PI3K activity by 
cell-penetrating analogs of cAMP (47). Therefore, it is 
possible that pioglitazone may act at points other than 
insulin receptor phosphorylation and association of IRS-1 
with PI3K. 
Proteins Elevated in KKAY Mice 
While the levels of the insulin receptor and p85a were 
found to be decreased in KKAY mice, the levels of GRB2, Nck, 
and Syp were found to be elevated, as is shown in fig. 2. 
Each of these proteins has been implicated in insulin 
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signaling to growth-related effects (116,141,148,155,157, 
161), as opposed to PI3K, which appears to have primarily a 
metabolic role {95,96,99,102). The difference in the levels 
of these proteins as compared to control levels were all 
more pronounced in epididymal fat tissue than liver, 
although all three were found to be significantly higher in 
KKAY liver than control. Pioglitazone had little or no 
effect on the expression of any of these proteins. 
GRB2 
Expression 
As shown in fig. 3, the expression of GRB2 was more 
than 3 times higher in KKAY fat than in the control animals, 
and pioglitazone treatment did not alter these levels. This 
increased expression may be partially due to the 
hyperinsulinemia and hyperglycemia of the animals because 
overnight incubation of 3T3-Ll cells with high insulin and 
high glucose caused a significant 35.7±8.1% increase 
{p<0.05, n=22) in expression. Although the change in 
cultured cells was much smaller than the difference observed 
in the animal model, such findings may imply that there is 
an effect of these agents on the expression of this protein. 
It is possible that the overnight incubation in high glucose 
and high insulin is not long enough to replicate the chronic 
condition of the diabetic animals, or that there are· other 
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factors involved in vivo that are absent in an in vitro 
model. Also, the streptozotocin-treated rats showed no 
alteration in the expression of GRB2 in either fat or liver 
(fig. 27 and fig. 28), suggesting that hyperglycemia alone 
is probably not a factor leading to increased GRB2 
expression. 
Association with IRS-1 or She 
The association of GRB2 with IRS-1 was not measurable 
with the methodology used in the present study. The studies 
that have shown association of IRS-1 with GRB2 have been 
done in cell systems constructed to overexpress the insulin 
receptor, IRS-1, or GRB2 (91,105,116,120,148). The physical 
association of GRB2 with IRS-1 may not be as strong or as 
abundant as the association of IRS-1 with p85a in vivo. 
Another possible explanation for our ability to detect p85a 
but not GRB2 in the anti-IRS-1 immunoprecipitates is the 
time course used. The time point used for insulin 
stimulation of the isolated adipocytes (2 minutes) was 
chosen because it was the time point at which maximal 
insulin-stimulated phosphorylation of IRS-1 was achieved in 
control cells (data not shown). This time course also 
seemed appropriate for measuring p85a association, since the 
association with IRS-1 was measurable in the stimulated 
control cells (fig. 11). The stimulation of glucose 
transport (18) appears to occur more rapidly than the 
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stimulation of growth-related effects (104,145) by insulin, 
and therefore a longer time point may be required for 
detection of GRB2 in anti-IRS-1 immunoprecipitates. 
Another reason that GRB2 may not be detectable in anti-
IRS-1 immunoprecipitates in this study is that GRB2 is found 
to associate with another protein, She, to a much greater 
extent than with IRS-1 (142). Future studies should be 
directed at measuring the regulation of She and its 
association with GRB2 in this model, since the higher 
expression of GRB2 in KKAY mouse fat was the largest 
difference compared to C57 control mice observed in this 
study. 
Possible Downstream Effects of Increased GRB2 Expression 
The elevated expression of GRB2 in KKAY mice has 
several possible implications in cell signaling, presuming 
that higher levels of this protein increased insulin 
signaling through this pathway. One possible explanation 
for the increased GRB2 expression in these animals is that 
this elevated expression is a compensatory mechanism brought 
about by the diabetic condition. First, evidence exists for 
the association of dynamin with GRB2, and the subsequent 
activation of the GTPase activity of dynamin by insulin 
stimulation (140,154). Dynamin function may be involved in 
the pinching off of coated vesicles from the plasma membrane 
for endocytosis, and it could thus be involved in receptor 
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internalization (154). If the high insulin levels in KKAY 
mice do indeed cause an increase in insulin receptor 
internalization and degradation, then more GRB2 may be 
needed to meet the increased demands for receptor 
internalization in these animals. This theory is consistent 
with the findings in 3T3-Ll adipocytes where high insulin 
and high glucose caused an increase in GRB2 expression (fig. 
20). It is also consistent with the absence of a difference 
in GRB2 levels between control and streptozotocin-treated 
rats, since the insulin levels in streptozotocin-treated 
rats are lowered (fig.27 and fig. 28). One might even 
expect a decrease in the expression of GRB2 in IDDM if this 
were actually the case, unless a basal level is maintained 
even in the absence of high insulin levels. 
Another mechanism by which an increased GRB2 expression 
may compensate for the diabetic condition involves the 
expression of glucose transporters. Adipose tissue contains 
both GLUTl and GLUT4 glucose transporters, although GLUT4 is 
the predominant species (21,187,188). GLUTl is present in 
many tissues, and is believed to be responsible for basal 
glucose uptake (21,188), while GLUT4 is known to be the 
transporter responsible for the majority of insulin-
stimulated glucose uptake in fat and muscle tissue 
(21,95,187,188). In prior studies, the expression of GLUT4 
was shown to be significantly lower in epididymal fat from 
KKAY mice as compared to control C57 mice, and KKAY mice were 
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also nearly unresponsive to insulin stimulation of glucose 
uptake {18). Therefore, the lower levels of GLUT4 and PI3K 
p85a (fig. 1) in adipose tissue could contribute to the 
insulin resistance of KKAY mice, since both have been 
implicated in insulin-stimulated glucose uptake {21,95,99, 
102,187,188). In contrast to this insulin-stimulated 
pathway, the levels of GRB2 (fig. 2) and GLUTl (Bonini, 
Dailey, Colca, White, and Hofmann, submitted for 
publication, September 1994) in adipose tissue from this 
model of insulin resistance were much higher than control 
levels. GRB2 binding to phosphorylated IRS-1 or She causes 
it to bind to and activate the guanine nucleotide exchange 
factor Sos, leading to activation of ras {116,141,144,148). 
Activated ras binds to and activates raf-1, which then 
phosphorylates MAP kinase kinase. Overexpression of 
constitutively active forms of either ras or raf-1 in 3T3-Ll 
adipocytes has been shown to increase the expression and 
activity of GLUTl, resulting in increased basal glucose 
uptake {149-151). Such findings were consistent with the 
concordantly higher expression of GRB2 and GLUTl in KKAY 
mice, as well as the higher basal glucose uptake measured in 
adipocytes from these animals compared to those from 
nondiabetic controls {18). 
Further evidence for a role of GLUTl upregulation as a 
compensatory response comes from studies in which 3T3-Ll 
adipocytes were deprived of glucose for 24 hr. This 
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resulted in an increase in GLUTl expression and a decrease 
in GLUT4 (193,194). During glucose deprivation, GLUTl was 
found primarily in the plasma membrane, and the increase in 
GLUTl was attributed to an increase in the rate of synthesis 
and stability of the protein. One potential role for GLUTl 
is to act as a stress response protein, and it is thought 
that the upregulation of GLUTl in this condition was a 
compensatory response to meet the glucose requirement of the 
cells (188,194,195). In the case of the KKAY mice, it is 
thus possible that the elevated levels of GRB2 and GLUTl are 
a compensatory response to the insulin resistance and the 
lower levels of IR, PI3K p85a, and GLUT4 in these animals. 
Although pioglitazone treatment did not significantly alter 
the levels of GRB2 in KKAY epididymal fat, it increased IR, 
p85a, and GLUT4 expression toward control levels, while 
GLUTl protein levels were decreased to control levels by 
pioglitazone treatment. 
Finally, GRB2 signaling has also been related to the 
growth and mitogenic effects of insulin (105,142,146). An 
increase in GRB2 may therefore route more of insulin's 
signal in this direction, since GRB2 was found to be rate-
limiting in insulin signal transduction to AP-1 and fos when 
IRS-1 was overexpressed in CHO cells (142). Therefore, a 
disruption of the proper stoichiometries in insulin 
signaling could alter the expression of other genes as well 




The expression of Nck, like GRB2, was higher in KKAY 
mice as compared to control mice (fig. 3), although this 
difference was not as large as that of GRB2. The higher 
expression was much more pronounced in adipose than in liver 
tissue. Also similar to the expression of GRB2 was the 
effect of high glucose and high insulin in raising the 
levels of Nck protein (fig. 20). This observation may 
indicate that these factors contribute to the higher 
expression of Nck protein in KKAY mice. Interestingly, Nck 
protein levels were decreased significantly by 29.1±6.5% 
(p=0.0123, n=9) in streptozotocin-treated rat liver, but not 
in fat tissue (fig. 27 and fig. 28). This result would 
suggest that insulin may somehow regulate Nck expression, or 
that other factors associated with hyperinsulinemia serve to 
upregulate this protein in KKAY mouse liver as compared to 
control animals. 
Because the nature of this protein is not entirely 
known, it is difficult to speculate on the possible 
downstream effects of Nck overexpression in KKAY mice. 
Nck has been shown to be a transforming oncogene when 
overexpressed (157,196), and it may have a serine/threonine 
kinase activity (156). There is no data indicating that 
KKAY mice have an increased incidence of tumor formation; 
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however, there is some evidence suggesting that serine 
phosphorylation of IRS-1 inhibits its insulin-stimulated 
tyrosine phosphorylation (197), although there is no 
evidence indicating that IRS-1 is a substrate for Nck. It 
remains possible that Nck could act as a negative regulator 
of insulin-stimulated phosphorylation of IRS-1. 
Association with IRS-1 
As in the experiments with GRB2, Nck was not found in 
IRS-1 immunoprecipitates at the time point used for the 
detection of p85a. 
Syp 
Expression 
The protein levels of Syp were also increased in 
insulin-resistant KKAY fat and liver as compared to 
nondiabetic control tissues (fig. 3). Unlike GRB2 and Nck, 
syp expression was not significantly altered in 3T3-Ll 
adipocytes pre-fed with high insulin and high glucose (fig. 
20). As demonstrated with GRB2 and Nck, however, the 
changes in expression observed with high insulin and high 
glucose treatment of 3T3-Ll cells were not as great as those 
seen in the animals, but it is possible that a longer 
incubation in this medium might result in an increase 
similar to that seen in the KKAY mice. 
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By contrast, Syp expression was significantly decreased 
in the insulin-deficient streptozotocin-treated diabetic 
rats as compared to the control rats in both tissues 
studied. This result suggests that under some conditions 
insulin levels may regulate the expression of Syp. This 
conclusion would be consistent with a catalytic role of Syp 
as a protein tyrosine phosphatase with the insulin receptor 
as a potential substrate (159). The increased basal 
phosphorylation of the insulin receptor in KKAY mice may 
require a higher level of tyrosine phosphatases to 
dephosphorylate the ~ subunit, which is required for 
receptor recycling (198). In the hypoinsulinemic state of 
IDDM, the receptor is not phosphorylated and the demand for 
syp to dephosphorylate it would be decreased. 
In addition to a potential role for facilitating 
receptor recycling, other actions for Syp have also been 
suggested. First, Syp has been shown to be a positive 
mediator of insulin signaling to mitogenesis (161). In rat-
1 fibroblasts stably expressing the insulin receptor, 
insulin-stimulated DNA synthesis was inhibited by 
microinjection of anti-Syp antibodies, phosphonopeptides 
containing the IRS-1 phosphotyrosine binding sites for Syp 
SH2 domains, or Syp SH2-GST fusion proteins by 60-90%, 50-
60%, and 90%, respectively (161). Secondly, the insulin 
receptor reportedly phosphorylated Syp in its SH2 domains, 
thus inactivating it (159). This suggests that in a· 
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condition where the insulin receptor is activated, Syp would 
be inactivated. Therefore, the high basal phosphorylation 
of the insulin receptor in KKAY mice could be altering Syp 
function. 
Association with IRS-1 
As in the case of GRB2 and Nck, Syp was not detectable 
in IRS-1 immunoprecipitates from the isolated adipocytes at 
the time point studied. As mentioned above, the association 
of all three of these proteins with IRS-1 had been 
discovered using systems where one or more of the components 
(the receptor, IRS-1, GRB2, Nck, or Syp) were overexpressed, 
or using systems with peptide sequences corresponding to 
pYXXX sequences of IRS-1 or SH2 domains of the other 
proteins. Most, if not all of the work done concerning 
these factors has been done in such systems. Therefore, 
although these associations are most likely real, they may 
not be measurable when present at normal physiologic levels 
in the in vivo system used in this study. 
To complicate the matter, the immunoprecipitation 
methodology results in including the immunoprecipitating 
antibody in the final pellet. When this pellet is disrupted 
by adding Laemmli buffer and boiling, the IgG heavy and 
light chains of the immunoprecipitating antibody become part 
of the sample to be run on the gel. The IgG heavy chain 
migrates as 50 kDa (fig. 11), while the IgG light chain 
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migrates as 25 kDa (data not shown). Both chains cross-
react with the anti-mouse secondary antibody used for the 
detection of the co-precipitating proteins. Nck and GRB2 
migrate as 44.2 and 25.7 kDa, respectively, and thus their 
signals may be obscured by this cross reactivity of the 
heavy and light IgG chains of the immunoprecipitating 
antibody with the secondary immunoblotting antibody. 
Significance of Alterations in Signaling Components 
Alterations as Contributing Factors to the Development 
of NIDDM 
Because the pathophysiology of KKAY mice closely 
resembles the symptoms of NIDDM in humans, several of the 
alterations observed in KKAY mice may contribute to the 
onset of NIDDM. While the lower insulin receptor levels in 
KKAY mice are most likely secondary to the hyperinsulinemia 
of these animals, this certainly would contribute to insulin 
resistance. Insulin resistance of peripheral tissues would 
result in elevated blood glucose levels, thus leading to 
further increased insulin release. High circulating insulin 
would in turn decrease the number of receptors by 
internalization and degradation. Such a decrease in 
receptor number would thus exacerbate the diabetic 
condition. 
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The receptor kinase defect measured in KKAY epididymal 
adipocytes would similarly contribute to the development of 
diabetes. Increased glucose and insulin levels inhibit the 
insulin receptor kinase (42,43,177,199-201). Accordingly, 
diminished receptor kinase activity would contribute to 
insulin resistance, thus leading to further elevation of 
blood glucose and circulating insulin levels (1). 
Likewise, the inability of insulin to acutely stimulate 
phosphorylation of IRS-1 and the subsequent association with 
and activation of PI3K in these receptor-defective cells 
would also decrease the sensitivity of the cells to insulin 
due to the connection between PI3K activity and GLUT4 
translocation and activation (95,96,99,102). The decreased 
amounts of PI3K p85a (fig. 2) and GLUT4 (18) in KKAY mice 
would also exacerbate this condition. The lowered 
expression of p85a in KKAY mouse fat did not appear to be 
due to the diabetic condition, and may thus be a 
contributing factor to the initial resistance of adipose 
tissue to insulin. 
The increased expression of the other three proteins 
could all potentially play a role in contributing to the 
insulin resistant condition, especially if proper 
stoichiometries of signaling components are required for 
proper signaling (142). In the case of KKAY mice, where 
the stoichiometry of these early signaling components is 
much different than in the normal C57 mice, proper signaling 
could be disrupted. This could result in routing the 
signals that enter the cell in inappropriate directions. 
Alterations as Compensation for Insulin Resistance 
152 
The higher expression of GRB2 in adipose tissue of KKAY 
mice over control levels was the most dramatic change seen 
in this study. As an early insulin signaling component 
upstream of ras and MAP kinase, GRB2 has been implicated in 
regulation of cell growth (105,142), mitogenesis (105,142), 
gene expression (142), protein synthesis (44,116,144,202), 
and glucose transport (116,144,149,151). Therefore, an 
alteration at this upstream level could have a profound 
effect on many cellular processes. As discussed above, it 
is possible that GRB2 overexpression is a cellular 
compensation for the insulin resistance of the cells in two 
respects. First, GRB2 overexpression could lead to 
activation of ras, which could then result in increased 
GLUTl expression and activation (149,151). This could bring 
glucose into the insulin resistant cells without GLUT4 
recruitment, thus accommodating the elevated blood glucose 
levels. Secondly, the association of GRB2 with dynamin and 
the role dynamin may play in receptor-mediated endocytosis 
suggests that increased GRB2 expression could be an attempt 
by the cell to turn off the insulin signal by increasing 
endocytosis. Alternatively, GRB2 may be upregulated as a 
response to the increased demand for internalization~ It 
would be interesting to measure the levels of GRB2 and 
dynamin in tissues of diabetic patients. 
Pioglitazone as an Antihyperglycemic Agent 
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Pioglitazone treatment had very little effect on the 
proteins studied, with the exception of raising the levels 
of p85a in KKAY fat to control levels and partially 
correcting the receptor number. Each of these corrections 
were lessened in importance by studying the function of 
these proteins. The insulin receptor tyrosine kinase was 
not significantly corrected, nor was the association of p85a 
with IRS-1. Therefore, it seems likely that pioglitazone 
elicits its effects at points other than these early 
signaling components. However, there is evidence to suggest 
that it may act on PI3K directly (47,48), in which case a 
correction of p85a protein by pioglitazone may still be 
functionally significant. The inability to measure many 
effects of pioglitazone at this level does not decrease its 
clinical importance in any way, since the fact still remains 
that pioglitazone is a potent antihyperglycemic agent which 
also acts to lower blood insulin levels, triglycerides, and 
hepatic glucose production (20). The exact mechanism of 
pioglitazone action remains to be elucidated. However, as 
mentioned in the above discussion, there are reports of 
thiazolidinediones affecting receptor tyrosine kinase 
activity (16,42-44), mRNA stability (40), PI3K activity 
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(47,48), and expression of genes encoding GLUT4, 
(18,41,203), lipoprotein lipase (203), glucose-6-phosphate 
dehydrogenase {203), GLUT! (19,41,203), adipsin (41), ap2 
(41), and phosphoenolpyruvate carboxykinase (19). It is 
quite possible that one or more of these effects could bring 
about some of the others. 
The clinical trials of another compound of this class, 
troglitazone, have been very favorable. Troglitazone 
increased insulin sensitivity and glucose tolerance in obese 
patients with either normal or impaired glucose tolerance 
prior to the study (46). Therefore, this class of insulin 
sensitizers, the thiazolidinediones, could be used to treat 
type II diabetes in the future (46). 
Caveats of this study 
As in any study of this kind, it is important to 
remember that an animal model of diabetes is not exactly the 
same as the actual disease in humans. Therefore, although 
KKAY mice display quite a few of the same symptoms as type 
II diabetics {36,37), they are not diabetic humans. Also, 
NIDDM is most likely a polygenic disorder with different 
defects in different populations of affected individuals, so 
one model would not suffice to demonstrate the actions of a 
drug or the sites of defects. In addition, due to the 
nature of the breeding required to produce KKAY mice, that 
is, the crossing of an obese mouse with a glucose-intolerant 
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one, there is no genetically related normal control with 
which to compare them. C57Bl/6J mice were used as control 
mice because they have blood insulin and glucose levels 
analogous to normal humans, and they respond well to insulin 
(18,37). However, these are two different strains of mice, 
so even though insulin signaling components may be altered 
in their expression in KKAY mice relative to C57 mice, they 
may not necessarily be involved in the onset of the diabetic 
condition. 
The other two models used have their own limitations as 
well. While 3T3-Ll adipocytes pre-fed with high insulin and 
high glucose may help to isolate the effects of these 
factors on fat cells, this model is limited in that the 
other factors involved in type II diabetes such as high 
triglyceride levels (20,36,37) or TNFa (204) are not 
present. Streptozotocin-induced IDDM is also not a perfect 
model due to the possible effects of streptozotocin on other 
cell types expressing GLUT2. If this compound were indeed 
cytotoxic to liver or kidney cells (205), then 
streptozotocin treatment could result in alterations in the 
physiology of the animals which may not occur in IDDM. 
Lastly, although this study has identified alterations 
in the expression of some early signaling components in this 
model of insulin resistant diabetes, many of these 
alterations were found to be associated with the diabetic 
condition itself. It is quite possible that the alterations 
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observed in this study are a result of one or more other 
defects in downstream signaling or glucose metabolism. Such 
defects could cause insulin resistance, resulting in 
hyperglycemia and hyperinsulinemia, which may in turn alter 
the expression or function of the insulin receptor, IRS-1, 
PI3K, GRB2, Nck, or Syp. Therefore, although the above 
results help to increase our understanding of type II 
diabetes and insulin resistance, they must be interpreted 
with the understanding that these are just pieces of a much 
larger puzzle. 
Summary and Conclusions 
The purpose of this study was to determine if the 
expression or function of early insulin signaling components 
were altered in an animal model of NIDDM compared to 
nondiabetic animals, and also to determine if the 
antidiabetic agent pioglitazone corrected or compensated for 
any of these defects. The results of this study show that 
the expression of the insulin receptor, PI3K p85a, GRB2, 
Nck, and syp was indeed altered in obese diabetic KKAY mice 
compared to control nondiabetic C57Bl/6J mice. In addition, 
the tyrosine kinase activity of the insulin receptor was 
found to be defective in insulin-stimulated 
autophosphorylation of the receptor ~-subunit and 
phosphorylation of IRS-1 in adipocytes isolated from KKAY 
mice compared to control adipocytes. As a consequence, PI3K 
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p85a association with IRS-1 following acute insulin 
stimulation was also impaired in KKAY adipocytes. While the 
altered expression of the insulin receptor, GRB2, and Nck 
was most likely due to the hyperglycemic and 
hyperinsulinemic condition of KKAY compared to nondiabetic 
mice, the lower levels of p85a in fat tissue of KKAY mice 
may not have been due to the high glucose and high insulin 
levels in these animals. Therefore, the lower expression of 
PI3K p85a in KKAY fat may contribute to the onset of 
diabetes in this model, while altered expression of the 
insulin receptor, GRB2, Nck, and Syp may have resulted from 
the diabetic condition. Pioglitazone treatment of KKAY mice 
had limited effects on the signaling components studied, 
although administration of the drug fully corrected the 
altered p85a levels in KKAY fat to control levels. However, 
the amount of p85a associated with IRS-1 in acutely-
stimulated adipocytes isolated from pioglitazone-treated 
KKAY mice was not increased over that observed in adipocytes 
from untreated KKAY mice. 
The observed alterations in insulin signaling are 
likely to be a result of the insulin resistant condition as 
well as contributing factors to the development of overt 
NIDDM. Because there are many different pathways involved 
in insulin signaling, insulin-sensitive cells in pre-
diabetic animals may upregulate certain factors to 
compensate for a defect elsewhere in signaling or 
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metabolism, and this may explain the increased GRB2, Nck, 
and Syp expression in cells with decreased insulin receptors 
or PI3K p85a. Such compensatory measures may delay the 
onset of severe NIDDM until the altered stoichiometry of 
signaling molecules can no longer make up for the deficit or 
until the stoichiometry is altered in such a way as to 
inhibit appropriate signaling. While further work is needed 
to determine if such compensatory mechanisms exist, this 
study has identified several alterations associated with 
insulin resistant diabetes in this animal model of NIDDM. 
Hopefully, these results will contribute to our 
understanding of diabetes mellitus and the development of a 
more efficient treatment for such a prevalent disease. 
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